Category Archives: Stocks to Watch

OncBioMune Pharmaceuticals, Inc. (OBMP) Preparing to Commence Phase II Clinical Study of ProscaVax™ Cancer Vaccine

February 11, 2016

OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products. The company’s lead product candidate, ProscaVax™, is a novel prostate cancer vaccine that’s scheduled to commence a phase II clinical trial in the coming weeks after recording promising results in its phase I clinical trial, which was completed late last year.

Unlike many leading treatment options, ProscaVax is being developed to treat prostate cancer in its early stages, allowing patients to build up an immunity that helps their bodies combat the disease with little or no toxicity. OncBioMune’s revolutionary technology introduces molecules known as antigens into the body in order to stimulate an aggressive immune response before the cancer becomes too advanced. In its phase I clinical trial of ProscaVax, an impressive 70 percent of patients who received three vaccines demonstrated increased immune response to prostate-specific antigen (PSA), a protein produced by cells of the prostate gland that can aid in the early detection of prostate cancer. This result, in addition to the candidate’s exemplary safety profile, bodes well for ProscaVax moving forward.

Leveraging a proprietary vaccine technology designed to boost the immune system’s natural ability to protect the body, ProscaVax is expected to be marketable and extremely profitable upon FDA approval, potentially becoming the standard of care for prostate cancer treatment. According to data from the American Cancer Society, about 220,800 new cases of prostate cancer were diagnosed in the United States last year. In total, the disease accounts for more than 27,500 deaths each year, making it the second leading cause of cancer death in American men.

Despite its prevalence, prostate cancer remains one of the most survivable forms of cancer, with a 10-year survival rate of roughly 98 percent in cases discovered in the local or regional stages. However, survivability is greatly impacted if the disease goes undetected into an advanced stage. In cases where prostate cancer has spread to bones, organs or distant lymph nodes, the five-year survival rate drops from nearly 100 percent to just 28 percent, according to ZERO. This statistic further highlights the potential benefit of ProscaVax, particularly in early stage prostate cancer cases.

Leading market research firm BCC Research valued the global market for the prevention and treatment of prostate cancer at $26.1 billion in 2011, and the firm forecasts the market to surpass $50 billion by next year. This growth will be led by the drug therapeutics sector, which is expected to sustain an 18 percent compound annual growth rate through 2017. As OncBioMune prepares to commence its phase II clinical trial of ProscaVax, this market performance could foreshadow an opportunity for the company to achieve strong financial growth following FDA approval and commercialization of its innovative treatment option.

Through an agreement with Lincoln Park Capital Fund, OncBioMune has secured $10 million in funding with which to help finance the upcoming phase II clinical study of ProscaVax. This strong cash position, along with the early promise of the company’s cancer vaccine technologies, makes OncBioMune an attractive play in the rapidly evolving oncology space.

For more information, visit

Let QualityStocks Help You Navigate the Small Cap Market Terrain

Simply put, the small cap market is huge. Nearly 8 out of 10 companies that publicly trade in the United States have a market capitalization of less than $500 million. A surprising 40% of the businesses that trade on Nasdaq have a market capitalization of less than $250 million.

Yet these companies get very little if any analyst research coverage on Wall Street. You may have 52 analysts covering a $468 billion company like Apple, but practically no one covering the small cap company. The investment news media consisting of broadcasts media like CNBC or the magazines and financial newspapers also rarely mention small caps. As a result, the small cap’s stock price rarely reflects the company’s future prospects.

Yet small companies are the true leaders of innovation and creativity. Large companies are bureaucratic monstrosities. Think of the film Office Space where computer engineers stuck in cubicles feel their creativity is stifled while they are focused on pleasing middle management writing Testing Procedure Specification (TPS) reports. Large corporations have become totalitarian work environments where the CEOs are acting as dictators looking over Stalinesque bureaucracies and even their brightest staff members feel as if they are merely renting themselves to the company for a living. The large organizational hierarchies of big cap companies are slow in making decisions and require sticking to established stagnant procedures. Startups require innovative entrepreneurs, and that typically isn’t in a job description for a large company. An innovative entrepreneur would most likely be deemed a threat by corporate middle management.

Small cap companies are hampered by little if any bureaucracy and this leads to rapid decision making, fast adaptability to quick changing markets, and a willingness to take on the risk of new ideas. Large companies sometimes throw large amounts of money to innovate and get nowhere due to ineffective internal communication within their own departments. Clear communication among internal staff and a lack of funds triggers small companies to come up with different, unique, solutions to solve the problems that lead to innovations.

Small cap entrepreneurs are the visionary business people that do market research, create business plans, seek out investors and financing, and then strive to create products and services that utilize a country’s resources. They are the true job creators, and not the management of large corporations that seek to enhance profits by off-shoring labor or replacing people with automation. They are the value waiting to be unlocked in the small cap market.

Let QualityStocks become your portal to small cap investment success

QualityStocks can be your first step to researching small companies on the leading edge of entrepreneurial innovation.

For over 8 years, QualityStocks free daily newsletter has been providing quality investment ideas to small cap investors. QualityStocks delivers the only newsletter tracking the stock tips of hundreds of other investment newsletters, and providing a ‘One-Stop Look’ at the daily highlights of the small cap market. Once you begin subscribing to the QualityStocks daily newsletter, you will wonder how you ever managed without it.

For a free subscription, visit

Let us hear your thoughts below:

Lightlake Therapeutics, Inc. (LLTP) Targeting Addictions and Related Disorders with Platform of Innovative Intranasal Naloxone Solutions

February 10, 2016

Lightlake Therapeutics, Inc. (OTCQB: LLTP) is a specialty pharmaceutical company engaged in the development of pharmacological treatments for substance abuse, addiction and eating disorders. In December 2014, the company entered into a global licensing deal with a subsidiary of Adapt Pharma Limited to develop and commercialize Lightlake’s innovative intranasal naloxone opioid overdose reversal treatment, NARCAN® Nasal Spray. As per the terms of this deal, Lightlake could receive potential development and sales milestone payments totaling more than $55 million – including a $2 million milestone payment following FDA approval and a $2.5 million milestone payment following the first commercial sale of NARCAN in the U.S. – in addition to double-digit royalty fees.

In November 2015, NARCAN was approved by the U.S. Food and Drug Administration for the emergency treatment of known or suspected opioid overdose. This approval marked the first time that naloxone –the trusted choice of healthcare providers to reverse the effects of opioid overdose for more than 40 years – was approved for distribution in the U.S. in a non-injection delivery method. Since its approval, momentum to increase access to naloxone has been on the rise. Late last year, President Obama included a call to make naloxone more readily available as part of a major initiative to address the nation’s opioid epidemic.

The commercial potential of NARCAN, to be marketed by Adapt, is expansive. In 2013, opioid overdose related deaths claimed nearly 24,500 lives in the U.S., accounting for roughly 52 percent of all drug overdose deaths, according to the Centers for Disease Control and Prevention. In total, prescription opioid abuse costs accounted for approximately $55.7 billion in 2007, with about 45 percent of all spending attributed to healthcare expenses.

In addition to its efforts to address the domestic opioid crisis, Lightlake has also completed a phase II clinical trial for its naloxone nasal spray to treat binge eating disorder (BED), a condition resulting in a lack of control when eating foods that are high in sugar, fat or salt. According to clinical data, the company’s nasal spray is well-suited to treating BED because it remains in the brain for two hours – the duration of a typical binge – without inducing negative side effects, such as a loss of interest in exercise, which are common with long-lasting opioid antagonists like naltrexone and nalmefene. Lightlake has also announced plans to conduct a Cocaine Use Disorder study in collaboration with the National Institute of Drug Abuse in the future.

With President Obama allocating $133 million toward the opioid epidemic in 2016 and guidelines from the Department of Health suggesting that naloxone could eventually become a standard script accompanying the more than 240 million opioid prescriptions written every year in the U.S., Lightlake, through its licensing deal with Adapt, is well positioned to record strong financial growth in the months to come. Look for the company to benefit from royalties stemming from this licensing agreement as it continues to advance its promising clinical pipeline targeting the treatment of BED and cocaine use disorder.

For more information, visit

Halitron, Inc. (HAON) Follows Strategic Business Model to Acquire PRD Holdings and PiecesInPlaces

Aligned with its business model to acquire and roll-up sales, marketing, and manufacturing companies, Halitron, Inc. (OTC: HAON) this morning announced its fourth and fifth acquisitions since 2015: PRD Holdings, Inc., a U.S. holding company for a Mexico-based factory; and PiecesInPlaces, a leading direct marketing brand.

PRD Holdings owns several factory investments in Mexico. These factories produce a wide array of products utilizing base materials in the print industry, as well as plastic-based product lines. The 12,000-square-foot main factory is located just a few miles over the border from San Diego, California, where 20 employees and a diverse line of equipment are capable of producing over $20 million in annual sales at full capacity.

In the $150,000 stock acquisition of PRD Holdings, Halitron purchased the corporation, equipment, raw material, finished goods and the know-how within a “very talented management team and employee base to produce goods with high quality at low costs.”

“PRD Holdings Inc. improves gross profits by over 35% with the acquisition,” Halitron CEO Bernard Findley stated in the news release. “We are now vertically integrated and can operate at very attractive margins due to a number of key factors including low labor rates, NAFTA, and distribution costs.”

Halitron also acquired the PiecesInPlaces brand in an asset sale from Plastic Retail Displays, LLC for an additional $27,895 and 4,016,469 in restricted common stock. PiecesInPlaces primarily sells vinyl file folders, pages and pouches to medical, dental and manufacturing businesses looking for ways to efficiently and safely transport important documents throughout an operational process.

In this transaction, Halitron acquired assets including a customer list totaling over 40,657 customers, the website, and digital artwork files utilized for print and email blast campaigns. Halitron said it expects the acquisition to add an additional 35% gross profit margin by manufacturing the products it sells to the end user.

“NDG Holdings Inc., a digital marketing acquisition from January 2015, will be able to grow the brand dramatically over the coming years. NDG Holdings maintains a strong analytical focus specifically on digital marketing which has a solid synergy with PiecesInPlaces,” Findley stated.

With these new acquisitions, Halitron said it is on pace to generate over $10 million in sales over the next three years, including its current pipeline of acquisitions.

For more information, visit the company’s website at

Stellar Biotechnologies, Inc. (SBOT) Releases Financial Results for Fiscal Quarter Ended December 31, 2015

February 9, 2016

On Monday, Stellar Biotechnologies, Inc. (NASDAQ: SBOT) (TSX-V: KLH), the leader in the sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), announced its financial results for its first fiscal quarter ended December 31, 2015. According to the report, the company successfully leveraged the increased visibility and improved access to institutional investors provided by its recent uplisting to the NASDAQ Capital Market (completed on November 5, 2015) to drive a 130 percent year-over-year increase in quarterly revenue.

“We are pleased to report good momentum heading into 2016, with what we believe are positive indicators for our core KLH business,” Frank Oakes, president, chief executive officer and chairman of Stellar, stated in the news release. “We are focusing on continuing to increase sales revenue, and we are working to expand our commercial and clinical opportunities with new collaborations.”

One such collaboration was proposed on January 20, 2016, in the form of a joint venture between Stellar and Neovacs, S.A, a leading biotechnology firm focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. The purpose of this proposed joint venture is to produce Neovacs’ Kinoid product candidates using Stellar’s KLH. The term sheet also outlined the possibility of manufacturing other KLH-based immunotherapies on behalf of third party customers in the future. As of writing, this proposed joint venture has yet to be consummated.

Additional highlights from Stellar’s financial report include:

  • The company generated total revenues of $488,160 for the three months ended December 31, 2015, compared to $212,661 for the three months ended December 31, 2014
  • Total expenses for the quarter were $1.8 million, compared to $1.5 million for the same period in 2014; the company attributed this increase to a combination of NASDAQ listing fees, compensation increases, increased share-based compensation and increased investor relations activity
  • Stellar’s working capital as of December 31, 2015, was $8.97 million, compared to working capital of $7.49 million as of September 30, 2015
  • The company maintained positive shareholders’ equity of $9.6 million and approximately 8.45 million shares outstanding as of December 31, 2015, compared to shareholders’ equity of $8.0 million and approximately 7.98 million shares outstanding at September 30, 2015

To view the full financial report, visit

Stellar has applied decades of specialized aquaculture science to a pharmaceutical industry challenge, creating the only KLH production facility of its kind in the world and establishing itself as the world leader in the sustainable manufacture of this important immune-stimulating molecule. The company’s customers and partners include multinational pharmaceutical companies, renowned research centers, and developers of active immunotherapies and therapeutic vaccines.

For more information, visit and

QualityStocks’ Tiered Rating Service Exposes Risk and Rewards Transparency

February 5, 2016

QualityStocks has rated more than 3,000 fully reporting OTC companies as an extension of its commitment to protect investors. Taking this commitment a step further, QualityStocks has also used the information gained from tracking hundreds of online newsletter firms to measure their legitimacy.

The OTC companies and research firms are rated based on their investor relations and transparency practices. QualityStocks has placed these companies into one of five tiers based on their compliance with market regulations, available information, transparency to shareholders, trust within the investor community, and the value of their product and/or services: QSP (QualityStocks Partner); QSV (QualityStocks Verified); QSL (QualityStocks Limited Information); QSN (QualityStocks No Information); and Caveat Emptor (Buyer Beware).

Trading OTC stocks poses a significant risk to any investor; those investors who are successfully managing an OTC portfolio know the importance of thorough due diligence. The QualityStocks rating service is a convenient and complementary tool designed to aid a trader’s individual research.

“Transparency is absolutely critical in this market. Our team has researched each company on our list to examine their fundamentals and apply an appropriate rating,” Michael McCarthy, Managing Director of QualityStocks, stated when originally announcing the service. “The result is a valuable tool that investors can use to quickly separate more trustworthy companies from more risky investments.”

To see the list of rated newsletter firms, visit:

To see the list of rated companies, visit:

Torchlight Energy Resources, Inc. (TRCH) Well-Equipped To Profit amid Cheaper Oil with Premium Acreage Metrics in Texas and Kansas

February 4, 2016

In a tight oil market where the WTI price recently dipped below $30 a barrel again on the NYMEX, ranging down to around $26 a barrel in January (making it about half as expensive as milk on the Chicago futures market), only the best of the best can survive and thrive. Investors looking for E&P companies to add to their portfolios will want to focus on players that have a good mix of low lifting (production) costs, a solid footprint in established domestic plays with low jurisdictional risk and a balance sheet that is relatively clear of debt overhang.

One such company is Plano, Texas-based Torchlight Energy Resources (NASDAQ: TRCH), which, in this regard, made huge strides last year, achieving a total elimination of senior debt, divestment of non-core assets, and a successful reduction of overall lifting costs to under $15 a barrel. At the same time, the company has honed its primary focus and has set its sights on the potential billion-barrel Orogrande Basin discovery ( (WolfPenn) in West Texas, where it owns a 47.5 percent working interest on 168,000 acres alongside Founders Oil and Gas, LLC. Torchlight drilled the Rich A-11 well (6,091 feet) on the Orogrande Project in March last year and subsequently executed a $50 million JV farm-out agreement with Midland, Texas-based Founders Oil and Gas, who initiated frac work on the well in November (

Torchlight’s five-year Orogrande lease (which offers exceptional five-year renewal terms) covers the majority of the Orogrande Basin, and the approximately 1,400 feet of pay being targeted here (at a highly economical depth of 4,000 to 6,100 feet) was originated by famed Permian Basin geologist Rich Masterson. Masterson, a recipient of the 2014 Hearst Energy Award for Technology, is the guy who originated the famous Wolfbone play in the Delaware Basin using a combination of old school mud log perusal, sample analysis, and pure experience-based instinct. The Wolfcamp and Bone Spring shales, readily characterized by high oil content and liquids-rich natural gas, are a key feature of the multi-horizon Delaware Basin, which is the foundation for horizontal development in the Greater Permian. The Orogrande formed at the same time as the Delaware and Midland basins, and the company expects a nice 80/20 mix of oil and high BTU gas from the analogous siltstone present at Orogrande.

The core siltstone target is a 700-foot interval of clean/contiguous pay that will be digested in two sections, with the lower section receiving the initial effort’s attention, and being used to establish production potential, as well as behavioral characteristics. A full suite of logs on the Rich A-11 were analyzed by Haliburton (NYSE: HAL) and found to be very promising, with superb shows in a variety of formations and good overall permeability. Moreover, while around 100 units of background gas were anticipated during drilling, Torchlight encountered as much as ten times that amount and core results showed good pay in the analyzed zones, with over 2,000 pounds of virgin pressure. There is a lot to be excited about here for Torchlight and its investors, as the estimated ultimate recovery (EUR) potential based on analogous Midland Basin EURs is in the neighborhood of four to six million barrels per section, with as many as eighteen horizontals per section.

Now, Torchlight isn’t just a one-trick pony, mind you. The company has an impressive (yet streamlined) portfolio of operated and non-operated positions under its belt, including the Marcelina Creek Project in South Texas, with its prime access to the Austin Chalk, Buda, and Eagle Ford formations. Marcelina is surrounded on all four sides by leading Eagle Ford producers; there are as many as seven horizontal drilling locations for all of the pay zones on the lease, and the lease actually offsets an excellent Buda field drilled by none other than Exxon (NYSE: XOM). The company has three producing wells with a combined BOPD of around 60 bbls already – 100 percent of CAPEX is paid by two of the company’s non-op industry partners, and Torchlight is preparing to drill a second Austin Chalk well sometime here in Q1.

On February 1, Torchlight announced a successful re-entry to one of its over 20 drilling locations on the Marcelina Project’s lease, where the company owns 75 percent WI on a 1,080-acre block, as well as a 50 percent WI on a smaller 280 acre block. The company’s Johnson #4 was drilled out laterally into the Austin Chalk about 2,500 feet and has subsequently shown increasing fluid and gas entry (, with 540 bbls over three eight-hour days, and liquids-rich gas up to 80 percent oil cut. With the shut in tubing holding steady around 470 PSI and good swab results thus far, Torchlight is quite excited about forthcoming initial production figures from this recompleted well that was previously running only 10 BOPD. Investors should keep an ear to the ground in coming weeks for an update from the company on the Johnson #4 and take note of how Torchlight has unlocked serious potential here at Marcelina from what was a marginally producing well – a feat which indicates similar potential across the company’s promising asset base and also reinforces the validity of its exploitation thesis that is being applied selectively thereto.

Torchlight also has a JV with Ring Energy (NYSE MKT: REI) to do E&P in the massive Hugoton Field area of Kansas, where the company is matching Ring Energy’s lease cost by drilling wells, and stands to end up owning a 50 percent interest across the entire 17,000-plus acre block. With numerous shallow pay zones around 5,200 feet, ranging from the Chase Formation through to Mississippian Age carbonates, cheap vertical well completion totals of around $550,000, and anticipated initial production levels in the neighborhood of 100 to 300 BOPD – Torchlight has every reason to be eager about seeing new well starts here in Q2 targeting the Morrow Formation.

In addition, Torchlight has some choice assets at the Cimarron Project outside Oklahoma City in the Edmonds Field that it is currently selling, and has already announced the first of six intended sales. This first sale, to Husky Ventures, will reportedly bring in over $1.4 million net from a $4.6 million price tag, and has already produced a partial cash closing for the company.

These are exciting times for this lean and mean E&P junior, which is focused squarely on profitable domestic drilling, as well as working interest programs with a near-term payback window.

For more information, visit

Pudo, Inc. (PDPTF) Offers a Creative Solution to End the Hassles of Package Pickup and Delivery

Named one of the most innovative public technology companies by the Canadian Innovation Exchange in 2015, Ontario-based Pudo, Inc. (OTCQB: PDPTF) represents one of the latest “why didn’t I think of that” ideas. The company’s idea, now available across Canada and the U.S., is a customizable pick-up and drop-off service, allowing anyone to specify one of thousands of third-party locations where packages can be picked up or dropped off for delivery.

What that means for the consumer is that they don’t have to worry about not being at home for a delivery or trying to get to the post office or a distant shipping center before it closes. Instead, they can have the package delivered to what the company calls PUDO Points, which can be a nearby convenience or grocery store or even a gas station, any one of thousands of places that are part of the company’s growing partner network. The consumer is notified by email when the item arrives, and then simply picks the package up there, at locations that are convenient to reach and open long hours, 7-days-a-week. Additionally, anyone can also ship packages from the same locations, at times when other options are closed. For the consumer the only requirement is that they become a free PUDO member.

It’s a service that is obviously great for the consumer, but it’s also valuable to the partner-store because of the increased traffic it draws. As the PUDO user community grows, greater traffic will be generated. PUDO supplies partners with technology to coordinate shipments, and provides courier arrangements to attract foot traffic and PUDO members for domestic and international shipping. PUDO members receive discounts on their shipping and stores earn revenue. In addition, PUDO gives training to ensure consistent service standards are met.

PUDO already has affiliate agreements with some of North America’s best-known retailers, including Amazon (NASDAQ: AMZN), eBay (NASDAQ: EBAY), Hudson’s Bay (OTC: HBAYF), and Walmart (NYSE: WMT), and it has recently entered into a marketing agreement with Innovative Marketing to provide PUDO with advertising and investor relations services. The company is now planning to raise up to $1.375 million through a non-brokered private placement, to “pursue the expansion of their location network in Canada and the United States, pursue strategic partners and retailers, and for general working capital”.

For more information visit: or

Halitron, Inc. (HAON) Lays Tracks for Success Built on Strong Acquisition, CEO Acumen

February 3, 2016

There’s hardly an industry or company that wouldn’t benefit from a profitable, strategic acquisition. Identifying a qualifying candidate, conducting due diligence, obtaining the financing, and executing the overall acquisition is where it gets tricky, but for the management team at Halitron, Inc. (OTC: HAON), well-calculated and successful acquisitions are first nature.

Focusing on sales, marketing and manufacturing businesses, Halitron strategizes to acquire bankrupt, distressed or insolvent companies and roll them into one operating infrastructure. The company recently entered into three separate letters of intent regarding profit-generating acquisitions expected to generate over $1 million in annualized sales. With completion expected in the first quarter, the company says these acquisitions will serve as the base of operations from which Halitron will explore future add-on acquisitions.

One specific challenge of the typical acquisition model is managing the costs associated with manufacturing, distribution and overhead. Halitron overcomes this obstacle by targeting several strategic acquisitions to maintain a low overhead for manufacturing, distribution, sales, and marketing techniques, primarily focusing on highly scalable digital marketing.

The company aims to take advantage of NAFTA and low DUTY costs, as well as low freight expenses, by owning the brands that sell to the end user, using its company-owned manufacturing center, and then distributing the products from a single distribution center in Tijuana, Mexico.

This business model enables Halitron to operate at high gross margins and implement online digital marketing techniques designed to drive sales growth of the brands it owns.

“Throughout the fourth quarter we focused on building a pipeline of acquisitions to lever a business model that includes a strong manufacturing base located just over the border from San Diego, California,” Halitron CEO Bernard Findley stated in a news release earlier this week. “Halitron, Inc. will acquire recognized brands that primarily sell product throughout the U.S. market. By manufacturing product and selling to the end user, this vertically integrated business model will be able to operate profitably and will be developed as a platform to absorb newly acquired businesses and then ‘roll’ them into the existing infrastructure.”

Findley has 20 years of experience working with small- to mid-size businesses. The first part of his career focused on growth opportunities in which he would build up sales and sell the businesses, and the latter part orchestrating a roll-up of 16 bankrupt, insolvent, and distressed brands. He has worked in many industries like medical devices, promotional products, and direct marketing, and over the past five years has rolled up and then exited 16 brands that, without his guidance, were bankrupt or out of business. Today, these brands exist and are operating under new owners.

As CEO of Halitron, he now applies his knowledge of how to take advantage of strengths within a business, reshape the business plan, and then execute on the deliverables.

For more information, visit the company’s website at

Pulmatrix, Inc. (PULM) COPD Treatment Candidate Reinforces Sweeping Potential of Company’s Proprietary iSPERSE Inhaled Dry Powder Tech

February 1, 2016

According to the latest official data published by the American Lung Association, the extremely debilitating and incurable progressive lung disease known as chronic obstructive pulmonary disorder (COPD) currently impacts as many as 24 million Americans ( The WHO estimates that by 2030, COPD will be the third leading cause of death and has ruled the disease a global epidemic. This statistic is, unfortunately, already true here in the U.S., where we have around 13.6 million cases currently diagnosed. COPD is actually a catch-all term for a host of lung diseases and associated ailments, like chronic bronchitis (increased mucus and inflammation) and emphysema (progressive alveoli damage), as well as refractory asthma and bronchiectasis (scarring/enlargement in damaged airways), to name but a few.

Naturally, because there is no cure, there is a sizable and growing treatment market for COPD, and one whose growth is being spurred on globally by an increasingly elderly population. In fact, the U.S. Department of Health and Human Services estimates that the older population in America alone will increase by some 120 percent through 2060. Compared to 2013’s ratio of about 14 percent (one out of every seven citizens), the number of COPD patients will more than double over this interval, to a total somewhere around 100 million.

Given that women are at particular mortality risk ( due to a sizable uptick in female smokers starting around the late 1960’s, and that women have an inordinate susceptibility to COPD when compared to men, due to their smaller-on-average lungs and the fact that estrogen plays a key role in the worsening of the disease, COPD-related death is notably higher among women. The roughly 7 million women in the U.S. who are currently diagnosed with COPD are not only severely debilitated by an inability to breathe properly, they face a higher risk of having their lives cut short by this disease, which was historically considered to be more of a man’s disease. A four-fold increase in fatalities among women over the past three decades has thrown a bright spotlight on how misdiagnosed the disease is among women, but the problem still persists, meaning that the emergence of new and easy to use treatments are highly sought after by this eager demographic.

Thankfully a number of treatments have already emerged to help prevent complications, such as airflow obstruction and bronchospasm, in COPD patients, including GlaxoSmithKline’s (NYSE: GSK) Anoro Ellipta, a so-called LAMA/LABA (long-acting muscarinic antagonist/beta agonist) once-daily, which was designed to also help maintain profitability for GSK as its mainstay Seretide/Advair (salmeterol and fluticasone) product is opened up to generic competition. One of the big hurdles generics have faced, however, is the difficulty in getting the delivery mechanism, an inhaler, properly designed – a factor which has led to much slower than expected onset of generic competition for GSK. Novartis (NYSE: NVS) also made progress in this same area last year with solid results in a pivotal U.S. Phase III clinical trial of twice-daily QVA149 (indacaterol/glycopyrronium bromide) and NVA237 (glycopyrronium bromide), as well as a more recent expansion of its relationship with Qualcomm’s (NASDAQ: QCOM) Qualcomm Life subsidiary, aimed at powering Novartis’ next-gen Breezhaler delivery system for its COPD portfolio (Onbrez, Seebri and Ultibro).

According to leading business intelligence provider GBI Research, the global COPD market is estimated to be worth approximately $11.3 billion ( and is on-track to grow by around 38 percent over the next few years, reaching upwards of $15.6 billion on the strength of LABA/LAMA bronchodilators by 2019. One of the extremely attractive contenders amid this multibillion dollar market is clinical stage biopharma Pulmatrix (NASDAQ: PULM), which has already completed a Phase 1b in patients with moderate to severe COPD using its branded generic bronchodilator PUR0200, for which there is currently no generic competition. PUR0200 has demonstrated efficacy at a much smaller dose than the reference target and the Phase 1b also clearly documented the efficiency of what is the company’s first small molecule formulation using its iSPERSE inhaled dry powder technology (, via comparison with traditional lactose blend formulations.

This is great news for the company and indicates to investors the potential for PULM’s technology, considering how iSPERSE now very strikingly appears to have the potential to enable delivery of entirely new classes of compounds directly to the lungs, something not possible with traditional lactose delivery technologies. An R&D partnership with global pharmaceutical developer and generics juggernaut Mylan (NASDAQ: MYL) in Europe spells big things for Pulmatrix’s PUR0200, and the drug could become the first branded generic for what is a roughly $5 billion segment of the larger global COPD market.

Moreover, the company has a robust IP position with some 37 issued patents worldwide covering its core dry powder technology, iSPERSE (inhaled small particles easily respirable and emitted), a proprietary platform solution that hurdles many of the lagging formulation problems facing the industry today that are typically seen with other lactose blend and metered dose inhaler technologies. Because iSPERSE particles don’t require a carrier such as lactose and can be engineered to carry anywhere from less than one percent to more than eighty percent of an active pharmaceutical ingredient (API), Pulmatrix has an extremely versatile delivery technology on its hands that is suitable for a wide range of drug loading roles – from small molecules, to peptides and proteins, or even antibodies. Pulmatrix could go toe to toe and even surpass sector heavy-hitters such as AstraZeneca (NYSE: AZN) and Bayer (OTC: BAYRY) in certain areas of the COPD market with this technology, and the company’s team of engineers have a deep understanding of the iSPERSE platform that spans the implantation gamut, from feasibility to clinical manufacturing, something which makes PULM a force to be reckoned with when it comes to novel inhalation products.

Indeed, such formulation prowess is just the tip of the iceberg for PULM’s iSPERSE platform, as the technology features numerous other characteristics that set it apart from competitors when it comes to significantly improving the treatment of a whole host of pulmonary diseases, as well as opening the door to important new inhalation products with important characteristics such as reproducible, one-step, scalable manufacturing – using a unique spray drying process that offers high quality, consistent yields of end product, which are completely independent of specific API physical chemistries. When you stack this advantage up against the optimum dispersibility across a range of flow rates, noting that iSPERSE formulations nevertheless feature consistent emitted dose and particle sizes, one can see that you get an easy to churn out, reliable dosing solution, a solution which is right for all patient populations and which uniquely addresses the problem of delivery variance from patient to patient.

Additionally, because iSPERSE allows for the delivery of macromolecules and biologics such as antibodies, peptides and nucleic acids across such wide range of drug loads – and because the technology enables the creation of dual and even triple homogenous combinations of multiple drugs – this platform technology is an ideal vehicle for Pulmatrix’s future candidates, and the Pulmatrix pipeline ( already offers some other exciting candidates alongside its lead, such as PUR1900 and PUR1500, designed (respectively) to treat the pulmonary fungal infections that affect half or more of all cystic fibrosis patients, as well as the loss of lung tissue oxygen transport capability common in idiopathic pulmonary fibrosis.

PUR1900 is particularly interesting, as it has been shown to be both active and potent in animal models (, achieving high lung concentrations and low systemic exposure, and because it would be the first ever inhalable anti-fungal for cystic fibrosis. Because PUR1900 directly targets aspergillus infection – which is typical of several other conditions such as suppressed immune function among leukemia-related chemotherapy or tuberculosis, and is seen in non-invasive nose, ear and eye infections – there are tantalizing upper limits when it comes to PUR1900’s broader applicability.

With a $1.7 million NIH research grant under its belt to work on an inhaled anti-fibrotic with Celdara, Inc. (, as well as a strong cash position of some $22 million ( that should see development efforts at the company through to the middle of next year, Pulmatrix is in an enviable position, with a robust pipeline of candidates, the capital muscle, and the bedrock tech to back up its aspirations. The company has a truly impressive drug delivery/manufacturing technology in iSPERSE that should continue to produce upside moving forward and investors will want to keep a close eye on PULM for news regarding further PUR0200 developments that are on the immediate horizon.

Take a closer look, visit

Skyline Medical, Inc.’s (SKLN) STREAMWAY System Proving its Value in Risky Healthcare Setting

Healthcare waste has the potential to infect hospital patients, healthcare workers and the general public. While roughly 85% of the amount of waste generated in the healthcare industry is non-hazardous, the remaining 15% is hazardous and may be infectious, toxic or radioactive. That’s according to the World Health Organization (WHO), which cites particular concern about infection with HIV, hepatitis B and C – only a few of many possible infectious diseases – for which there is strong evidence of transmission from improper healthcare waste management.

Obviously, medical personnel, especially in emergency situations, aren’t always privy to whether or not a patient’s fluids are infectious, and outdated manual fluid handling methods, which require hand carrying and emptying filled fluid canisters, present an exposure risk and potential liability.

Skyline Medical, Inc. (NASDAQ: SKLN) is in the market to buck these risks with its fully automated, patented, FDA-cleared waste fluid disposal system that virtually eliminates staff exposure to blood, irrigation fluid and other potentially infectious fluids found in the healthcare environment.

The company’s STREAMWAY® System fully automates the collection, measurement and disposal of waste fluids. Aside from providing a measure of safety against biohazard exposure, the system is designed to: reduce overhead costs to hospitals and surgical centers; improve compliance with Occupational State and Health Association (OSHA) and other regulatory agency safety guidelines; improve efficiency in the operating room, and radiology and endoscopy departments; and help eliminate the approximately 50 million potentially disease-infected canisters dumped into U.S. landfills each year.

Installed in or on the wall, STREAMWAY features an illuminated touch screen that provides the user control over surgical suction levels and displays automated measurement of volumes. The single patient procedure filter and tissue trap both prevent cross contamination and allow for tissue retrieval. When it comes time to clean up, the user detaches the filter, connects the cleaning solution bottle, and activates the five-minute clean cycle using the touch screen.

In one case study, STREAMWAY user Fran Hahn, BSN, RN, CNOR at Huntingdon Valley Surgery Center in Pennsylvania stated, “I cringe when I have to do an arthroscopic procedure in one of the rooms without STREAMWAY. It’s so much easier and safer to use than canisters.”

Read the entire cast study here:

Unlike Hahn’s experience, Skyline has found that the majority of radiology and imaging rooms, in particular, are not even aware that automated fluid disposal technology exists. To counter this finding, Skyline recently partnered with the Association for Radiologic & Imaging Nursing (“ARIN”) to market Skyline products and services to medical professionals performing paracentesis and thoracentesis procedures.

“Our research has shown that most radiology and imaging rooms do not currently use, nor are they aware of automated fluid disposal technology, despite the major potential safety and cost benefits. As it is the nurses and technologists that often perform these procedures and can help influence purchasing decisions, we expect our partnership with ARIN to create new sales opportunities,” Josh Kornberg, president and CEO of Skyline, stated in the news release announcing the partnership.

As an ARIN sponsor, Skyline has access to nurses in the imaging and radiology space, and, on April 3, will have the opportunity to attend the ARIN Spring Convention in Vancouver, where the company’s sales representatives will demonstrate Skyline products to nurses, technologists and other industry decision makers.

In the first nine months of 2015, Skyline shipped and sold 15 of its STREAMWAY Systems, and by November had initiated 12 new trials of the system in eight different U.S. states. From past experience, the company’s trial strategy yields significant success.

“Our sales strategy encourages hospital and surgical centers to trial the STREAMWAY, as we are confident that the unique benefits of our exposure prevention system will be quickly recognized throughout the facilities. This approach has proven to be successful with our trial-to-sale conversion rate standing at an impressive 98%,” Kornberg stated. “There are currently more than 48 hospital and surgical centers using our STREAMWAY System in the United States. We are looking to rapidly expand our customer base through the implementation of an aggressive sales and marketing strategy over the next year, which will include a dedicated salesforce and a network of distributors.”

This “aggressive sales and marketing strategy” includes international expansion, and Skyline has started the process of filing international patent applications in Canada and select European countries for the technologies and processes applied in the STREAMWAY System.

For its domestic focus, Skyline is gaining mounting confidence in the capability and acceptance of its technology.

“Our success selling to major hospitals indicates that medical centers are shifting away from, and we are displacing, alternative fluid management solutions that have been in place for many years. For us to have achieved this, despite our limited sales and marketing capabilities, truly validates the quality and effectiveness of the STREAMWAY™ System. The STREAMWAY is currently installed in a wide variety of procedure rooms, including surgery, interventional radiology and endoscopy suites, demonstrating very significant market potential for the product. Moreover, we are starting to see repeat orders from some of these customers,” Kornberg stated in a previous news release.

As more medical facilities are seeing, STREAMWAY eliminates one of the most dangerous aspects of being a healthcare professional: handling surgical fluid canisters and their contents. With rising market acceptance, Skyline continues to focus on establishing STREAMWAY as the premier surgical fluid disposal device, providing an unprecedented standard of safety, efficiency and environmental benefits for hospitals and surgical centers worldwide.

For more information, visit

The Debate Over Tax Policy

January 29, 2016

Debate over tax policy is an obviously crucial issue because it impacts everything from various government services like police and infrastructure and judicial system and military funding, to having a successful educational system, and so forth.

Between the two political parties, one area of debate which hasn’t really been brought to close scrutiny is corporate taxation. Republicans argue that America has the highest corporate tax rate at 39.1%, which is well above the Organization for Economic Cooperation and Development (OECD) average of 24.1%. Democrats point out that if you look at the effective tax rate, the largest corporations of the S&P 500 are paying effective tax rates well below that level and typically average out to around 15%.

Essentially, due to years of lobbying the politicians, corporate lawyers have continuously changed tax rules to lean in favor of the largest of corporations. Transnational corporations effectively manage a type of tax arbitrage, where profits are realized in subsidiaries headquartered in parts of the world where the taxes are the least, and losses are realized in subsidiaries which are located in regions where taxes are the highest. Usage of subsidiaries with addresses in countries that act as tax havens, like the Cayman Islands, Switzerland and Ireland, have become a common practice. As a result, revenue to the government from the S&P 500 companies has plummeted over the years as can be seen below:

Corporate Taxes as a Percentage of Federal Revenue
1955 . . . 27.3%
2010 . . . 8.9%

Corporate Taxes as a Percentage of GDP
1955 . . . 4.3%
2010 . . . 1.3%

Individual Income/Payrolls as a Percentage of Federal Revenue
1955 . . . 58.0%
2010 . . . 81.5%

Since 2014, the above figures have generally stayed precisely the same. In other words, as corporations paid less, an even greater burden has been placed on individuals. About 54 of the S&P 500 corporations paid no taxes at all, with the majority getting refunds. For example, from 2010 to 2014, General Electric (GE) made $33 billion in profits, but paid zero in income taxes, and actually received $1.4 billion in tax refunds over that same stretch of time.

One way companies have been cutting their taxes is by corporate inversion, in other words, moving their headquarters offshore to cut their taxes. There is a progressive solution which is given the complicated name of single sales factor apportioned corporate tax. This simply means that if a company has only X percentage of its sales in the United States of America, it only pays taxes on X percentage of its earnings. So if a corporation has a mere 30% of its sales in the United States, it only pays taxes on 30% of its earnings. This was proposed by economist Michael Udell of the District Economics Group. Unfortunately, lobbying groups for special interests manage to succeed in allowing this concept to even be brought before Congress.

Real estate investment trust (REIT) structures have an effective tax rate of close to 10%, and are typically publicly traded real estate management companies that pay-out 90% of their taxable income as a dividend to shareholders. Supposedly, 75% of the REIT’s assets are supposed to be real estate. Over the past decade, however, many corporations have switched to REIT structures to cut their tax obligations. For example, prison management companies like Correctional Corporations of America (CXW) and GEO Group Inc. (GEO), cell phone tower management company American Tower (AMT), document storage company Iron Mountain (IRM), and timber company Weyerhauser (WY) avoided taxes altogether using a REIT structure, and it appears that the railroads and power line management companies may adopt this structure as well.

Setting aside corporations, what about taxes on individuals? Franklin D. Roosevelt had a top tax bracket for the rich of 91%. Of course, that isn’t 91% of all income as our tax system is a graduated structure with brackets. In today’s dollars, every dollar made above something like $1.4 million was taxed at 91 cents at the dollar. This tax bracket was lowered to 70% under President Kennedy and then cut down to as low as 28% under Ronald Reagan, and since then has been raised. What do we have today? A top rate of 39.6% for every dollar made above $406,751, and the rich rarely ever pay that. Most of the rich don’t have a salary that can be taxed as income but earn their money from a portfolio of stocks and bonds.

Taxes on cash dividends used to be taxed as ordinary income; however, that tax has been cut so those dividends are now taxed at 15%. Taxes on corporate bonds are taxed at the ordinary income rate, but if you put the corporate bonds into a fund or a unit investment trust, and then have the bond’s interest payments payed out as dividends to unit holders of that trust, you effectively lower that rate to 15%. Municipal bonds are free of federal taxes and, depending on the bond, may be free of your own state tax as well. Sales from long-term capital gains – stocks held more than a year – are taxed as a rate of 15%. As a result, the rich in the top 1% typically end up paying at an effective tax rate of 15%, which is well below the middle class that typically ends up at a 35% tax bracket. This is why famed investor Warren Buffet of Berkshire Hathaway (BRK.A) pointed out that his tax rate was well below that of his own secretary.

As mentioned, in the 1980s, Reagan cut the top tax bracket down to 28%. To make up for the decrease in government revenue, Reagan raised the payroll tax 11 times, which amounted to the largest tax increase on the middle class in history. He is better remembered for his tax cuts, but those cuts only benefitted the richest in American society.

Bottom line, not only is the bulk of the government revenue now coming from individuals, a great deal more is now coming from the middle class than it was in the 1950s. So, we went from a system in which the bulk of the tax burden was on capital and far less on labor. Now we are in a system where labor is subsidizing capital.

One of the dominant economic theories is supply side economics, which suggest that greater economic growth is achieved if capital is not taxed and is freed up to invest in assets which encourage job growth and grow the economy. However, historical data counters that narrative. Through what is referred to as globalization, U.S. multinational corporations have been investing since the 1980s in assets offshore seeking cheaper labor costs to enhance profit. For those assets not invested, they are hoarded in savings in other countries to the point where over $2.1 trillion of the S&P 500’s free cash is held in offshore tax havens.

The United States exhibited its highest growth rate in the 1960s when the highest marginal tax rate was initially at levels of 90%, 77%, and 70% throughout that decade, and far higher corporate tax revenue was collected as well. When wealthy elites paid their fair share of taxes, the country benefitted, and both the public and private sectors worked in better balance. Now we appear to be in a system where there is a distribution of wealth from the bottom 90% up to the wealthiest Americans. As a result, the middle class is shrinking, and our infrastructure is poorly funded and falling to disrepair. Republicans continually advocate for flat taxes, which act as yet another tax cut for the rich and further increases the tax burden on the middle class and the poor. Putting in place a more progressive tax structure while eliminating loop holes would aid in growing the middle class, and re-invigorating economic growth.

CEL-SCI Corp. (CVM) Building Shareholder Value, Using Perseverance and the Body’s Immune System to Fight Cancer

CEL-SCI Corp.’s (NYSE MKT: CVM) body of work with the human immune system is one of perseverance and a passion for survival despite odds that would make the vast majority of biotech companies fold their tents and choose easier endeavors. Faced with trending downturns in the biotech sector, limited funding, and an arduous clinical trial process connected with the development of its investigational therapy for advanced primary head and neck cancer, the company’s mission is now well within sight. CVM’s lead investigational immunotherapy, Multikine® (Leukocyte Interleukin, Injection), has been tested in Phase I and II clinical trials, and is now enrolling patients for a global Phase III trial.

The inception of CVM’s journey began at the Max Planck Institute in Germany in the late 1970s and has been fueled with science and research supporting the theory that the immune system is inherently a cancer fighter. Company founder, Maximilian de Clara, believed strongly that the immune system is pivotal in fighting this disease, but he did not have the technology to transition his concept to product. Brushing off discouragement, Maximilian funded the early Multikine research at the Max Plank Institute in 1978, founded CEL-SCI around the idea of Multikine in 1983, and later took CVM public.

The company’s mission is to improve the treatment of cancer and other diseases by utilizing the immune system. CEL-SCI Corp. aims to create shareholder value by developing unique therapies that address medical needs that are commonly unmet. The company is dedicated to developing its therapies using a scientific and data-driven approach.

CVM’s undying spirit aims to be science-based and data driven – taking no shortcuts on its road to drug development. The company is steadfast in its ethics and integrity while being economical in its daily approach to creating shareholder value.

Multikine is the registered trademark under which CEL-SCI has its investigational therapy. The proprietary name is subject to FDA review in connection with additional, anticipated regulatory submission for approval measures. Multikine has not been licensed or approved for sale by the FDA or any other regulatory agency at this time and its safety or efficacy has not been established for any use. Further research is required, and early-phase clinical trial results must be confirmed in Phase III clinical trials, which are currently underway. CEL-SCI Corporation is headquartered in Vienna, Virginia.

For more information on this company visit

Diamond-Centered Alliance Supplements Britannia Mining, Inc.’s (BMIN) Vision for 2016

January 28, 2016

Britannia Mining (OTC: BMIN), a natural resources development company focused on consolidating and trading a wide range of mineral commodities, this morning announced its partnership with Everledger Ltd. The alliance is of significance to Britannia’s vision for 2016, enabling the company to execute its growth strategy, address industry challenges by reducing risks, and add greater transparency in diamond procurement.

UK-based Everledger provides an immutable ledger for diamond certification and transaction verification in order to efficiently track the origin of diamonds. The company stores its ledger on the Blockchain, which was identified at the recent World Economic Forum in Davos as one of the fundamental elements of the Fourth Industrial Revolution.

For Britannia, this proprietary technology has the potential to incorporate tracking rough diamonds and possibly other high value minerals and metals from mine pit/shaft through to end-buyer.

“Our goal is to position the company to leverage the best practices for our downstream sales business. This year we plan to incorporate innovative and proven technologies to address some of the obstacles we have seen impede mineral commodity trading, such as slow inefficient paper based systems, risk, theft and fraud. We believe that this collaboration with Everledger presents the best opportunity for us to embrace state-of-the art digital solutions to reduce risk and improve the execution of trading deals,” Britannia CEO Kenneth Roberts stated in the news release.

Roberts provided more explanation of Britannia’s outlook for the upcoming year, indicating Everledger’s role in this plan.

“At the dawn of the Fourth Industrial Revolution, our vision is global and it is focused on addressing trading bottlenecks that are systemic. We anticipate announcing new major initiatives supporting this vision as this year progresses,” he said. “Managing risk lies at the heart of trading high value precious gems and metals. Digitization at source could go a long way to add value to due diligence, fraud detection, custody settlement and title transfer mechanisms. Last year we demonstrated that we can source quality products. This year, our focus is on adding an additional layer of transaction security to augment our offering and potentially speed up deal closing procedures.”

Roberts further outlines the company’s vision in an interview with Europe and Middle East Outlook Magazine ( scheduled for release January 29, 2016.

For more information, visit

Immune Therapeutics, Inc. (IMUN) and Partner Organizations at Major Milestone with Lodonal™ as HIV Treatment

The world’s countries differ in countless ways, but are similar in that they shoulder the task of protecting the health of their citizens. While the biggest health threats faced by emerging nations are communicable diseases such as HIV/AIDS, malaria and tuberculosis, these nations are also documenting rises in non-communicable disease such as cancer, diabetes and inflammatory disease. If drugs are available, many are hinged with high cost, complex administration and storage, significant side effects, or other challenges that prevent mass usage.

With decades of research behind it, naltrexone, or Lodonal™ as it is known internationally, is gaining global traction as a non-toxic, affordable and easy-to-administer therapy for both communicable and non-communicable diseases.

The U.S. FDA approved naltrexone 50 mg for the management of alcohol and opioid dependence in 1984; since then, many doctors in the United States have also prescribed low-dose naltrexone (LDN) to treat a number of indications, including multiple sclerosis (MS), Parkinson’s disease, Crohn’s disease, HIV/AIDS, cancer and other autoimmune and inflammatory diseases. While the mechanism of naltrexone in autoimmune diseases and cancer is still being researched, researchers have theories as to why LDN works on autoimmune diseases, cancer and inflammatory diseases.

In short, Lodonal/LDN helps the body heal itself by increasing the levels of endorphins (peptides produced in the brain and adrenal glands), which serve as powerful modulators of the body’s immune system. Lodonal attaches to opioid receptors in the brain and immune cells, temporarily blocking endorphins signals and causing the body to increase endorphin production. This boost of endorphin production helps facilitate the activity of stem cells, macrophages, natural killer cells, T and B cells and other immune cells. Lodonal also prevents immune system over activity, the crux of autoimmune disorders, and blunts the release of inflammatory and neurotoxic chemicals in the brain.

So how effective is LDN in such a wide range of indications? That’s what Orlando, Florida-based Immune Therapeutics, Inc. (OTCQB: IMUN) aims to find out. Immune Therapeutics has built a technology platform using patented immunotherapy to combat chronic, life-threatening diseases by activating and modulating the body’s immune system to enhance treatment.

The company’s most advanced clinical programs involve immunotherapy with met-enkephalin (MENK) and LDN, the latter of which the company is pursuing in additional investigations as a viable treatment for autoimmune conditions such as rheumatoid arthritis and MS; as an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery; and as a complement to antibiotics in the treatment of a variety of infectious diseases, including patients with HIV/AIDS, in combination with retroviral drug therapy.

In collaboration with AHAR Pharma and GB Pharma Holdings, Immune Therapeutics recently completed a bridging trial comprised of HIV-positive patients to confirm the safety and efficacy of Lodonal. Resulting data was submitted to Nigeria’s National Agency for Food and Drug Administration Control (NAFDAC) in connection with approval of Lodonal as an immune booster to improve health of those affected by HIV-positive status and others with compromised immune systems.

This milestone is of particular importance in sub-Sharan Africa, where an estimated 24.7 million people – 71% of the global total – live with HIV. Ten countries account for 81% of all people living with HIV in the region, and 50% of those live in Nigeria and South Africa. Additionally, Immune Therapeutics reports that 80% of people who do not have access to HIV treatment are in Nigeria, which adds weight to the fact that Lodonal can provide non-toxic stand alone or adjunct treatment for less than $0.90 a day.

For more information on the specifics of the trial, visit

In a news release announcing the completion, Dr. Nicholas Plotnikoff, Immune Therapeutics’ non-executive chairman, said, “We are excited about achieving this major milestone in collaboration with our partner organizations AHAR Pharma and GB Pharma Holdings. The shortened time frame of the Lodonal™ submission was facilitated by professionalism and thoroughness from NAFDAC. We look forward to continued cooperation with NAFDAC in the review of Lodonal™ in the hope of making a general immune booster and adjunct treatment for HIV+ patients.”

As part of this process, Immune Therapeutics in August 2015 signed a Letter of Intent with leading Nigerian pharmaceutical company Fidson Healthcare PLC for exclusive distribution rights in Nigeria and expects to finalize the agreement upon final NAFDAC approval for Lodonal.

HIV/AIDS remains one of three global public health threats, and, standing at the brink and waiting for NAFDAC approval for something with incredible potential to address this health concern, Immune Therapeutics continues to advance its pipeline for oncology and immunology – with LDN in phase 3 studies for MS, Chron’s UC and fibromyalgia and phase 2 studies for advanced cancers and HIV.

For more information visit

Liquidmetal Technologies, Inc. (LQMT) Leverages IP, Partnerships and Sales as Catalysts for Strong 2016

Liquidmetal Technologies, Inc. (OTC: LQMT) is the leading developer of amorphous alloys – unique materials capable of retaining a random structure when they solidify, in contrast to the crystalline atomic structure that forms in ordinary metals and alloys. As the first company to produce amorphous alloys in commercially viable bulk form, Liquidmetal has developed an explicit strategy for advancing the commercial adoption of its technologies. The basis for this strategy is a strong intellectual portfolio, valuable partnerships and a strong sales team.

More than double the strength of titanium, highly elastic, non-magnetic and resistant to corrosion, Liquidmetal alloys are a metallic glass that enable applications to achieve unprecedented performance and accuracy levels, making them ideal for medical, military, consumer, industrial and sporting goods products.

Liquidmetal has control of intellectual property rights for this technology with more than 70 U.S. patents – and the applications within this IP portfolio continue to expand. The company recently received an annual purchase order from CoNextions to produce a critical medical device component to be used for suture-based tendon repairs, and, in December, Liquidmetal began selling its Liquidmetal Hybrid Knife, which embodies a geometry that is impractical to produce with any other metal forming process.

“The ability of the Liquidmetal process technology to provide such a high level of part to part dimensional precision and repeatability is showcased by the precise fit of the knife blade and protector,” Paul Hauck, vice president of World-Wide Sales and Marketing, stated in a news release. “After more than 30 years of involvement with metal parts fabrication technologies, I have not witnessed anything like the precision of this molding technology…”

Liquidmetal manufactures its components through a network of Certified Liquidmetal Partners (CLP) comprised of leading alloy material suppliers, machine & mold manufacturers, government agencies, and commercial companies. This structure ensures that each CLP adheres to rigorous testing and certification requirements and means each customer who purchases Liquidmetal parts and services receives a consistently high quality.

The company also maintains the highest standards for itself and kicked off 2016 with news it has received its formal ISO 9001: 2008 certification, which the company says places it in a position to close the gap between early prototypes and high volume dual source to outsourced production.

Liquidmetal reported $42,000 in revenues for third-quarter 2015, down from $97,000 in the comparable quarter of 2014, but marking the fifth consecutive quarter with a significant sequential increase in the number of request for quotes (RFQs).

“In the third quarter of FY15 we again received over 100 RFQs and again achieved an all-time high. Just as significant about 25% of these RFQs came from Europe. RFQs are the lifeblood of our future and this significant quarter-over-quarter increase along with their ever-improving quality gives us substantial reason for optimism as we look towards 2016,” company CEO Tom Steipp stated in the third-quarter earnings call (

As Liquidmetals prepares to ramp-up production and shipment revenues in the upcoming year, customer education and confidence will play a vital role in its success. For this, Liquidmetals has a strong sales and marketing team.

“During the past 18 months, we’ve worked hard to assemble an internal and external team of sales and marketing professionals … The total team at Liquidmetal is now processing more than 100 RFQs per quarter and more than 200 general technology inquiries … The increasing number and quality of RFQs is a clear reflection of their significant contribution to educating customers on the design principals and material property benefits that come from our technology…,” Hauck stated in the quarterly earnings call.

After hitting several key milestones in 2015, Steipp says the company has built a solid foundation for the beginning and increase of production revenue in the year ahead.

For more information, go to

XLI Technologies, Inc. (XLIT) Nanotech Printed LightSheets Offer Durable, Efficient, Versatile Lighting Solution for Numerous Sectors

January 27, 2016

The promise of nanotechnology and our growing ability to manufacture new products at the nanoscale continue to make their presence felt in the commercial environment, with innovative solutions cropping up across numerous industries as diverse as biomedicine and lighting. Whether we are talking about revolutionary developments such as nanoviricides that could be the virus-fighting smartweapons of the future, or more efficient and easier to place industrial/consumer grade lighting for our homes and workplaces, the sky is the limit when it comes to the emerging applications of nanoscale manufacturing.

One of the publicly-traded companies at the forefront of this space today is XLI Technologies (OTC: XLIT), which has exclusive licensing rights for the entertainment industry (as well as specific automotive applications) when it comes to distribution of the proprietary nanotech Printed LightSheets™ powered by Cru Global Innovations ( and manufactured by New Jersey-based Triton Solar ( Currently the only global supplier to offer high quality, highly efficient printed solar cells, lighting, and batteries, Triton Solar, with its specialized nanotechnology manufacturing capabilities, has opened a huge door for XLIT in the entertainment and automotive sectors, thanks to the unique characteristics of Printed LightSheets.

The nanotech manufacturing of these beauties allows them to bend, be folded, or even cut without disrupting their primary function, making the Printed LightSheets (which come with their own transformer to provide power) ideal for a variety of lighting roles that hitherto were essentially impossible. The primary focus for XLI Technologies thus far has been the movie business, where the company is providing cutting-edge solutions in advertising and promotions aimed at the theatres, such as backlit poster and display stand lighting, as well as the motion picture production end of the business, where it is offering studios, distribution companies, and advertisers similar options, using its full range of standard display sizes, such as mini billboard (48″ by 96″), backlit (27″ by 40″), versatile (24″ by 36″), placement (22″ by 28″), and spot (18″ by 24″).

Lighting up prominent display surfaces of all kinds and shapes that hitherto could not be used to draw the consumer’s eye with advertising, such as benches, garbage cans, or even the floor, is a potential brand presence goldmine, and XLIT is selling the picks and shovels. The idea of putting backlit movie posters on the walls is now a time-honored tradition in most theatres, but XLIT has given theatre operators a way to cheaply and easily put the same displays right on the floor ( via a simple, but robust setup, helping to illuminate walkways and also captivate audiences at the same time with a unique display that pedestrians will marvel at. This same powerful lighting technology can be used to more easily and efficiently provide illumination for traditional wall displays or to bring attention to display stands that feature film iconography.

This is a gigantic market, which pulled down a $10.8 billion 2015 domestic gross (according to Box Office Mojo), up 3.7 percent from the MPAA’s official 2014 figure of $10.4 billion. MPAA figures for 2014 put the global box office take at around $36.4 billion on a hearty increase from China, which was up 34 percent year-over-year to become the first international market to exceed $4 billion in box office draws. This should give investors a clear picture of the global market potential for such lighting solutions, and the North American market where XLI Technologies is currently focused is particularly notable due to the vast majority of screens being tied to just the top four sector operators – Regal Entertainment Group (NYSE: RGC), AMC Entertainment (NYSE: AMC), Cinemark (NYSE: CNK), and Carmike Cinemas (NASDAQ: CKEC).

One need look no further than hot properties such as Disney’s (NYSE: DIS) Star Wars: The Force Awakens, to understand the market potential for XLIT. This single film currently has a domestic gross of over $880 million (as of January 25) and has done another $1.06 billion in the international market, making it one of the highest grossing films of all time, with just under $2 billion in global box office receipts.

The company’s recent debut of a turnkey advertising revenue program for theatres using the 24″ by 36″ Printed LightSheet, where XLIT sets up advertising sales for every placement sold, is an enticing draw for theatre companies, and one which should bring in many new clients for the company, as it generates significant recurring revenue without additional costs, while also promoting additional advertising sales. This program makes it easy for the theatre companies to adopt Printed LightSheet technology by offsetting capital outlays on the hardware and leading to profitability within the first three weeks of rollout. The program is similarly beneficial to XLIT, of course, yielding commissions and margins from the ad positioning opportunities the company creates in the process.

The unique value proposition of Printed LightSheet technology represents a significant efficiency upgrade as well when compared to existing solutions, efficiency that was recently documented by an independent third party entertainment and event production company, which specializes in supplying state-of-the-art lighting technologies to the industry. The independent test findings were even better than initially expected by XLIT and confirmed that not only do the units output roughly 800 lumens for 0.0625 Watts per square foot, they offer 100 percent light coverage with color temperatures of 4000K and 5800K, making them ideal for a variety of uses, from indoor or outdoor advertising, to displays, and reading.

In additional movie business news, XLIT’s wholly-owned Bosch International subsidiary recently secured a key marketing rights agreement with in-theatre video advertising platform TrailerSpots, which produces 30-second “Directed Imagination“ spots ( that can be run in any theatre and which play just after the commercials and before the theatrical trailers. Using all of the same in-theatre audio and video enhancements (including 3D) as the theatrical presentation, and presented in the same format and quality as the trailers, these highly engaging spots can be produced in-house by Bosch Technologies or utilize existing content. Since this timeslot is essentially universal across all theatres in North America and is typically used by the theatre company to plug their own brand or orient audiences to commonsense film-watching protocols, such as shutting off cell phones, there is a huge advertising opportunity here for XLIT. This is an opportunity which the studios’ marketing people should be clamoring for, as they won’t even have to pull the unique TrailerSpots when the film actually comes out.

Because Printed LightSheets can be cut and bent into almost any shape imaginable and are thus perfect for creating applied/embedded surface lighting in the automotive sector, XLIT is also emphasizing this sizable market moving forward. With offerings that range from exterior surface lighting like hood wraps and quarter-panel lighting, to customized advertisements and promotions like a company logo made out of Printed LightSheets, XLIT is in the pole position when it comes to making big waves in the automotive industry. These same products can be used for interior lighting as well, giving automotive manufacturers and aftermarket retailers the ability to create eye-popping illuminated headliners, as well as seats, floormats, interior door panels, and even custom displays.

Given the versatility of Printed LightSheets – which can be used in almost any configuration or shape, from 1” by 1” panels up to 800 square foot units, as well as their incredible durability in almost any weather condition thanks to the nanomanufacturing process – XLIT has another big opportunity in customized applications. From light-up benches in an industrial park or corporate compound, to backlit walls and interiors in the airline industry, there is a massive/untapped custom market for Printed LightSheets in addition to the core target markets of the film and automotive industries. A customized application market delimited only by the end-user’s imagination.

Take a closer look, visit

Forward Industries, Inc. (FORD) Settled Proxy Battle, Return to Profitability, Bayer Supply Extension are Positive Indicators Moving Forward

January 26, 2016

While just about every investor has likely heard of globally-recognized companies and brands such as Lenovo’s Motorola Mobility (OTC: LNVGY), Nokia (NYSE: NOK), Philips (NYSE: PHG) and Toshiba (OTC: TOSYY), or healthcare sector operators like Roche (OTCQX: RHHBY) and Johnson & Johnson (NYSE: JNJ), many remain surprisingly unfamiliar with the increasingly vital carrying case and protective solutions provider which reinforces these heavy-hitters: Forward Industries (NASDAQ: FORD). West Palm Beach, Florida-headquartered Forward Industries conceptualizes, designs and delivers an extremely wide variety of tailored carrying case and usability solutions for gadgets produced by these globally-recognized brands. These solutions are either packaged with the branded product or sold in the retail aftermarket, and they significantly enhance the functionality, as well as brand presence, of the core product.

Whether we are talking about a carrying case for portable electronic healthcare devices, such as the blood glucose monitoring kits used by diabetics, handheld bar code scanners used in a warehouse, GPS devices for recreation and navigation, firearms, or even the average consumer’s smartphone/tablet – chances are that Forward Industries makes a carrying case, clip, stand or other accessory that the reader has used. With a highly skilled team of innovators that work hand-in-hand with the company’s OEM clients (or their contract manufacturing firms) to custom design the perfect carry, protective or usability accessory and over three decades of experience leveraging the premium manufacturing metrics available in China and the Far East, Forward Industries is one of the most sought-after accoutrement design shops on earth today.

After Forward Industries has worked with the OEM customer and its sizable supply chain in Asia, consisting of 800,000 square feet of manufacturing capacity, the company then ensures that gold-standard quality control procedures are utilized in order to make certain that the commercially approved production units meet with the exacting specifications that have been laid out. The company’s logistical and global warehousing capacity, as well as its comprehensive compliance structures, have won Forward Industries mounting favor among the roughly 81 OEMs around the world with which the company currently does business.

One of the largest companies that FORD has such a tight-knit relationship with is Germany-based multinational chemical and pharmaceutical developer, Bayer (OTC: BAYRY), with whom Forward Industries recently signed a sizable carry case extension deal. This extension deal adds to a relationship stretching back several years and has FORD supplying the customized carrying cases that go with Bayer’s diabetic products all the way through to the end of 2018. Such a deal speaks volumes about how Forward Industries has become one of only a handful of trusted go-to suppliers chosen by healthcare and tech sector majors to handle the accessories for their most important products.

The Bayer extension deal should also give investors a hint as to how important the company’s proven abilities to satisfy the complex compliance demands within this heavily regulated industry are, especially when it comes to differentiating FORD from its numerous competitors. Little wonder then that the company’s Q4 financials (ended September 30, 2015) showed a 2.3 percent increase in gross profit percentages when compared to Q4 FY14, or the company’s 128 percent jump in gross profits over the same interval. FORD’s Q4 FY15 EPS of $0.03 per share was quite a feat considering the turbulence experienced by the company due to an expensive (now resolved) proxy battle and paints a stark contrast with the loss of $(0.08) per share seen during the same quarter in the prior year.

The company’s ability to turn profitability around so sharply despite the proxy battle, and its ability to shore up its OEM-focused presence with the Bayer deal, is a positive signal to markets about where the company’s CEO, Terry Wise, is taking Forward Industries this year. Consistently delighted multinational customers, who continue to praise FORD for its quality and cost-effectiveness, will most likely see this case and accessory designer through to a profitable 2016 – following up nicely on its return to the black, with two back-to-back quarters of solid profitability.

Forward Industries is now fully committed to mustering sustained momentum via the hammering out of long-term sourcing agreements with new and existing customers, as well as a broadening of its product mix, which should help FORD secure access to an expanding customer base. Innovation has long been the watchword at FORD, and its in-house conceptualization and design capabilities are a force in this sector that has to be reckoned with. Given that the company has the ability to go from co-creation sessions with the customer, through traditional art approaches and on into 3D modelling quite rapidly, rounding out the design phase with both traditional mockup and 3D printing, FORD should be able to continue landing new customers across the board with ease this year.

Already serving industries ranging from tech, medical devices and video gaming to military, government and automotive, the sky is the limit for Forward Industries when it comes to design. With warehousing and production in Shenzhen and Dongguan, China, as well as operational footholds in Tsim Sha Tsui, Hong Kong and Taipei, Taiwan, Forward Industries can offer unique scaling/sourcing benefits to its customers, and also has the global sales footprint to back it up. With sales offices in California and Indiana, as well as Switzerland – managed via the company’s wholly-owned Forward US and Forward Switzerland subsidiaries – FORD has the cost-effective manufacturing/supply capacity, as well as the key target market localized sales force strength, needed to really deliver in 2016 on its aspirations of continued profitability.

This is true whether we are talking about the $10 billion plus global glucose monitoring and diabetes management device market (Kalorama Information), or the smartphone market, which shipped around 1.44 billion units last year (IDC).

Take a closer look, visit

Among Ad Techs, Why Social Reality (SCRI)? CEO Gives Compelling Presentation at NobleCon12

January 25, 2016

There are a lot of players looking for relevance and roots in the crowded $15 billion ad tech (advertising technology) space. Capturing market share in this competitive industry requires aggressive strategy, new technologies, and the ability to successfully innovate and integrate into the evolving landscape.

While a handful of behemoths hoard the majority of ad tech market share, there’s plenty of room for smaller companies that can pull off the above-mentioned objectives to add their weight to the scale.

Los Angeles-based Social Reality is one such player. Using proprietary technology, Social Reality delivers a full suite of advertising and marketing tools and services that enable brands, agencies and publishers to target, reach and monetize their audiences. This six-year old company differentiates itself from other companies in many aspects.

Christopher Miglino, chief executive officer and one of the founders of Social Reality, has been in the ad tech game since the 90s and is moving the company forward at an impressive pace. He recently took the stage at NobleCon12 Investor Conference to showcase his company and how it is growing roots in the ad tech space.

Watch the full webcast here:

In short, Social Reality is building tools that brand marketers and advertisers and publishers can use to generate revenue from inventory or to buy media. The company’s core platform creates solid footing in the real time bidding (RTB) and social media markets, both of which are valued at $15 billion for 2015.

In 2014, Social Reality’s grasp in these markets generated revenues around $4 million and set in motion a reiterated forecast for $30 million in total revenues for full-year 2015.

“It’s been one of those fantastic years … we think we’ll continue to see growth into 2016. We have a lot of technologies in place now to help us make that transition of really giving our salespeople what they need to make it to the next level,” Miglino explains in his NobleCon12 presentation.

Targeting brand marketers, agencies, and online publishers, Social Reality’s sales team has built an impressive roster of customers and clients that include big names like Subaru, Time Warner Cable (NYSE: TWC), McDonald’s, Disney (NYSE: DIS), H&R Block, P&G, Wells Fargo (NYSE: WFC), State Farm, New Balance, Comcast (NYSE: CCV), Red Bull, Pantene, Sam’s Club, Kenmore, Toyota (NYSE: TM), American Red Cross and General Electric (NYSE: GE), Pfizer (NYSE: PFE) and several big pharmaceutical marketers.

Miglino’s NobleCon12 presentation provides extensive insight into Social Reality’s core platforms: SRAX (social reality ad exchange), SRAX social, SRAX MD for pharmaceutical companies. He walks through each of these products, describing their function and application, strategies for client retention and how they generate revenue.

In alignment with the prevailing trend of consolidation in the ad tech space, Social Reality boasts a strong and recent acquisition history. In 2014 the company acquired Steel Media, Social Spotlight Media and Five Delta – each of which contribute a unique component to the SRAX platform.

When you place Social Reality in a lineup of its peers, as Miglino does in the NobleCon12 presentation, you get a greater idea of who is who, what they’re doing to gain footing, and how/if they’re able to combat industry headwinds to achieve financial success.

“I think that we fit well within the eco system of the companies that are making money. We’ve had positive net income and we’re generating excess cash flow. We’ve run a really tight ship within the organization …,” he explains.

To sum up what a “tight ship” looks like for Social Reality, Miglino offers the following:

• Strong management
• Multiple recurring revenue streams
• Positioned in two multi-billion dollar markets
• Explosive year-over-year revenue growth
• Value accretive acquisition history
• Secured $25 million in financing

Closer inspection of the picture Miglino paints of Social Reality validates his confidence in the company’s ability to perform in an exciting space dominated by the big boys.

“It’s been a really exciting year this year for us. We think that we’re good at going out and finding a creed of opportunities in the market. We have another $10 million left on our line with Victory Park if there are other acquisitions for us to do,” Miglino tells the audience at NobleCon12.

The ad tech field is brimming with potential as it constantly changes with the tides of resources, innovations and products. By leveraging its core products and strong business model, Social Reality is showing it has what it takes to navigate the waters and achieve its full potential.

For more information, visit

The Guitammer Company’s (GTMM) Immersive ButtKicker® Low Frequency Audio Transducer-Driven 4D Experience Coming To More AMC Theatres

January 22, 2016

The degree of visual enhancement in film and TV during recent years has been astounding. With Digital Cinema Initiatives 4K standard in theatres and 4K UHD at home, as well as a resurgence of 3D stereoscopic films in theatres using technologies like RealD 3D (NYSE: RLD), Dolby 3D (NYSE: DLB) and IMAX 3D (NYSE: IMAX), films look better than ever on the big, and small(er) screen. Similar innovations in the world of audio, led by top players such as Dolby, DTS (NASDAQ: DTSI) and Sony (NYSE: SNE), have allowed for an unprecedented level of acoustical richness and fidelity, resulting in viewer immersion horizons unimaginable to previous generations.

However, even as consumers start to get their hands on technologies like Oculus VR’s Oculus Rift head-mounted display, or the comparable virtual reality device developed in collaboration with Samsung (OTC: SSNLF), the Gear VR, there is one dimension of sense perception that has yet to see similar advancements: touch-feel. This is where pioneering haptic-tactile (of or relating to the sense of touch) technology developer Guitammer (OTCQB: GTMM) really shines, with a rapidly emerging brand presence driven by its portfolio of patented and patent pending broadcast technologies like the award-winning line of ButtKicker low frequency audio transducers. Haptic-tactile events experienced by viewers may have a visual and auditory portion to them, but Guitammer takes it that extra step and really puts viewers in the game, or lets them experience movies in a whole new way by letting them “feel” the impact of a hockey player getting checked into the boards, or the force of an explosion narrowly escaped by their favorite heroes.

Guitammer’s dynamic haptic event transmission technology is now coming to more theatres across the U.S. than ever before, on the back of a sweeping new deal with AMC Theatres (NYSE: AMC) which will expand the company’s installed footprint of ButtKicker-enabled theatres via 34 new deployments, more than doubling GTMM’s existing install base with AMC. President of GTMM, Mark Luden, was keen to point out how mounting order growth among theatres is driven by audience/proprietor receptivity to this innovative technology, which allows viewers to actually experience haptic events physically. As this new feature picks up steam, with more and more theatregoers actively seeking out this enticing and hitherto unexperienced dimension of film, the potential upside for GTMM as the leading hardware provider is quite significant.

This is especially true when one considers that, globally, total filmed entertainment revenue is estimated by PwC as being on-track to experience a CAGR of 4.1 percent through 2019, hitting upwards of $104 billion, led by hot markets like China (14.5 percent CAGR) and Latin America (Brazil 6.4 percent, Argentina 11.5 percent). In 2014 alone, the MPAA reported a $36.4 billion global box office take, with China experiencing a 34 percent jump over 2013’s figures, even as the number of cinema screens worldwide grew by 6 percent. With blockbusters like Star Wars:
The Force Awakens
currently sitting on around $1.88 billion in worldwide gross, more than half of which came from the international market, the sky is indeed the limit for GTMM’s technology.

Westerville, Ohio-based Guitammer anticipates similarly robust growth moving forward in terms of adoption rates and estimates that some 2.5 million Americans will experience a ButtKicker enabled viewing after the company’s install base is bolstered by the new AMC additions. This end-user buzz feed system will in turn accelerate interest in Guitammer’s consumer grade solutions, driving sales of the company’s haptic-enabled broadcast services and hardware aimed at the home theatre market. The company’s technology is more musically accurate and considerably more powerful, as well as longer lasting, than competing voice coil shakers or other tactile devices, employing a magnetically suspended precision-guided piston that transfers vibration directly to whatever the unit’s housing is attached to.

Guitammer’s “4D Sports powered by ButtKicker” is a concept whose time has come and it is not hard to imagine this technology quickly proliferating out to the sports bar market. Because ButtKicker transducers accurately reproduce the feeling range of audio in a vastly more direct way than sound waves travelling through the air, and because when using headphones or speakers at a reduced volume the sound is completely isolated to the listener, the full range of possible implementations for this technology is immense. PwC estimates that global sports revenues were in the neighborhood of $145 billion last year (including factors like gate receipts), driven by rebounding TV advertising and an ongoing migration toward pay TV, as well as a return to the sponsorship space by financial services and automotive companies. It is no leap of faith to imagine ButtKicker devices in sporting arenas to help deliver a more realistic, front row seat experience to attendees at sporting events, even up in the cheap seats.

Delivering this level of powerful, concert-level audio directly to the listener, via a method that is driven by exacting capture and reproduction of remote haptic events, and in a fashion in which the user feels the event in perfect sync with (in the case of film) the audio and video – is something which has to be felt to be believed. To accurately comprehend the potential market for this technology, investors must experience it firsthand. Luckily, Guitammer has put together and maintains a Google Maps-based listing of venues where users can experience it for themselves. A listing which also illustrates how this incredible technology will soon be present on over 22,000 seats, in 11 countries, and in front of more than 100 screens worldwide.

Take a closer look by visiting, or head over to the company’s Facebook and Twitter feeds.

DreamTeamNetwork (DTN) is Platinum Sponsor for 2016 Disruptive Growth & Healthcare Conference – LinkedIn Page Now Ready to Follow

DreamTeamNetwork (DTN) is proud to announce its role as a platinum-level sponsor for the upcoming 2016 Disruptive Growth & Healthcare Conference, hosted by Source Capital Group, taking place in New York City February 10-11.

As a platinum sponsor, DTN has created and will manage a LinkedIn page specifically for the conference – the page will serve as a real-time hub where interested parties can take a look at what company is making its presentation and when, as well as a brief profile describing the specialty of each presenting company.

This one-of-a-kind conference will feature presentations from top executives of approximately 100 life science companies focused on solutions to unmet medical needs and growth companies with disruptive technologies and business models. The panels will cover regenerative medicine, immunotherapy, diagnostics, disruptive innovations and business models, disruptive holding companies, energy – clean tech, technology media & telecom (TMT), and a discussion regarding NOLs and rights offerings.

Attendees will include more than 400 institutional investors, accredited investors, family offices, analysts, registered investment advisors, wealth managers, source reps and their clients. If you’re not among those privy to attend, DTN has you covered.

Visit this link to follow the investor conference page and keep up-to-date on this exciting conference:

For more information visit

Cancer Genetics (CGIX) at the Forefront of Personalized Medicine

January 21, 2016

Cancer Genetics, Inc. (NASDAQ: CGIX) is focused on the development of personalized genetic testing for the detection of various cancers, with the goal of significantly increasing treatment efficacy while reducing healthcare costs. CGI’s scientific advisory board includes leaders in the areas of hematological malignancies, solid tumor cancers, pharmacogenomics, and clinical trials administration. The company’s growing patent base consists of molecular-focused patents for the diagnosis, prognosis, and risk stratification of difficult-to-treat cancers, based on what the company calls “unique algorithms that take into account multiple chromosomal regions associated with particular disease outcomes or treatment decision”.

CGI is heavily involved in the area of pharmacogenomics – determining the way genetics affects a patient’s drug response – to improve treatment and even help select trial populations for clinical testing. The company offers a number of pharmacogenomics testing services, including theranostic testing for various hematological and solid tumor cancers. In 2013, CGI helped form Oncospire Genomics as an equally owned joint venture with Mayo Clinic, designed to develop and commercialize NGS (Next Generation Sequencing) panels for unmet critical oncological needs. In 2014, CGI acquired Gentris, LLC, a pharmacogenomics testing, genotyping, and biorepository services company based in Raleigh, NC, with operations in China. That same year, the company also acquired India-based Bioserve Biotechnologies Pvt. Ltd., a leader in DNA related services in India.

Based in Rutherford, New Jersey, CGI also has operations in North Carolina and California, as well as in India and China. In addition, the company has research collaborations with cancer research and treatment leaders around the world, including:

  • Beth Israel Deaconess Medical Center
  • Cleveland Clinic
  • Columbia University
  • Groupe Hospitalier Pitié Salpétriêre, Paris
  • Huntsman Cancer Institute, University of Utah
  • Kamineni Hospital
  • Keck Medicine of USC
  • Mayo Clinic
  • Memorial Sloan-Kettering Cancer Center
  • Moffitt Cancer Center
  • National Cancer Institute
  • North Shore-Long Island Jewish Health System
  • University of Alabama School of Medicine
  • University of Iowa Cancer Center
  • Westchester Medical Center at New York Medical College

CGI’s President and CEO is Panna Sharma, founder of TSG Partners, a specialty life sciences consultancy and advisory company, where he directed the company’s strategic initiatives and growth strategy, including various public and private company turnarounds, establishing several life science capital markets indices that are still used in the life science industry.

For more information, visit

The Clorox Company (CLX): A True Global Conglomerate with Community Values

The Clorox Company (NYSE: CLX) manufactures and markets consumer and professional products worldwide. The company operates through four segments: Cleaning, Household, Lifestyle, and International. Clorox is a global company with leading brands that have become household names, including its namesake bleach and cleaning products; Green Works naturally derived cleaning products; Ayudín and Poett home care products; Pine-Sol dilutable cleaner; Fresh Step cat litter; Kingsford charcoal; Hidden Valley and K.C. Masterpiece dressings and sauces; Brita water filtration products; Glad bags, wraps and containers; and Burt’s Bees natural personal care products.

Clorox manufactures products in more than two-dozen countries and markets them in more than 100 countries. The company offers laundry additives, including bleach products under the brand Clorox, as well as stain fighter and color booster products under the brand Clorox 2 and home care products under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands.

Clorox also provides naturally derived products under the Green Works brand name; and cleaning and disinfecting products under the Clorox, Dispatch, Aplicare, HealthLink, and Clorox Healthcare brands. In addition, the company offers plastic bags, wraps, and containers under the brand name Glad; cat litter products under the Fresh Step, Scoop Away, and Ever Clean brand names; and charcoal products under the Kingsford and Match Light brands.

In addition to the products mentioned above, Clorox provides dressings and sauces under the Hidden Valley, K.C. Masterpiece, and Soy Vay brand names; water-filtration systems and filters under the Brita brand; and natural personal care products under the Burt’s Bees brand name. Additionally, the company offers dust wipes under the brand name Clorox; facial products and lip crayons and balms under the Burt’s Bees brand; and scents under the Glad, OdorShield, and Gain brands. It also markets its products under the PinoLuz, Ayudin, Limpido, Clorinda, Poett, Mistolin, Lestoil, Bon Bril, Agua Jane, and Chux brands.

Clorox strives to make everyday life better in the parts of the world where it does business by giving back to its communities. Whether it’s contributing to disaster relief efforts through donations of Clorox regular bleach, teaching classes at local schools or funding education, arts and culture programs, Clorox is committed to helping restore, enrich and protect its communities.

For more information, please visit the company’s website at

Nike, Inc. (NKE) Continues Worldwide Growth

Nike, Inc. (NYSE: NKE), headquartered in Beaverton, OR, is the world’s leading sportswear and sporting goods company, with a market cap approaching $100 billion. Founded in 1964 as Blue Ribbon Sports, and changing its name to NIKE in 1971, the company offers a full range of sports related clothing, accessories, and equipment through sports and department stores and shops worldwide, as well as directly to consumers over the Internet. Nike’s stated mission is “To bring inspiration and innovation to every athlete in the world”, adding that “if you have a body, you are an athlete”, the latter being a mantra used by legendary University of Oregon track and field coach, Bill Bowerman, who, along with Philip Knight, founded the company.

Philip H. Knight, a director of the company since 1968, is Chairman of the Board, and also served as company President for much of that time. Nike’s current CEO and President, Mark Parker, joined in 1979, using his experience as a competitive runner to design footwear for the company. Nike feels it has built its dominant position in the marketplace largely through its close connection with both the casual and professional sports community, and now serves the sports market on six continents. It continues to grow sales and market share.

In addition to its large Oregon headquarters, with over 8,000 employees, Nike has corporate locations in New York, Chicago, Los Angeles, Toronto, and Fort Worth. Its European headquarters is in the Netherlands, with operational and administrative centers in London, Paris, Frankfurt, Stockholm, Moscow, and several other locations. The Japan & Asia Pacific region is supported by key operations in Japan, Korea, India, Singapore, Malaysia, Indonesia, Vietnam, Australia, and other countries, while the Nike Greater China Campus, with nearly 2,000 employees, is located in Shanghai. Nike also employs more than 3,000 workers in Brazil, Argentina, Chile, Uruguay, Paraguay, Bolivia, and Mexico, and has operations in South Africa.

As a worldwide employer, Nike emphasizes its ongoing efforts to demand ethical working conditions from its suppliers and business partners, affirming detailed steps it continues to take to eliminate forced or bonded labor, and to incentivize changes that benefit workers throughout the supply chain. According to the company’s Standards for Compliance: “Nike uses third-party auditors to verify contracted factories are (in) compliance with laws. If a contracted factory is found to violate laws or Nike standards, it is responsible for improving performance against a master action plan. If the factory fails to make progress against that plan, they are subject to review and sanctions, including potential termination.”

For more information, visit and

Stellar Biotechnologies, Inc. (SBOT) Announces Joint Venture With Neovacs S.A.

Stellar Biotechnologies, Inc. (NASDAQ: SBOT), a California-based biotechnology company and world leader in the sustainable manufacture of keyhole limpet hemocyanin (KLH), a protein used for stimulating and measuring immune response, has announced plans to form a joint venture with Neovacs S.A., a French biotechnology company focused on an active immunotherapy technology platform.

The joint venture will be for the manufacture of conjugated therapeutic vaccines based upon Stellar’s proprietary KLH protein, specifically to produce Neovacs’ Kinoid product candidates, including IFNa-Kinoid, and to potentially produce other KLH-based immunotherapies on behalf of third party customers. However, negotiations are not complete and will continue regarding details of the venture’s exact ownership and organization, though it is anticipated that initial ownership will be 70% with Neovacs and 30% with Stellar. The announcement was also careful to make clear that there can be no assurance the joint venture will be consummated or, if consummated, will achieve the expected results.

Stellar’s Chairman and CEO, Frank Oakes, said of the proposed venture: “We believe the proposed joint venture could be a very positive development for both Stellar and Neovacs. It would enable us to work together to ensure the successful development of IFNa-Kinoid at scale but, importantly, we anticipate building manufacturing infrastructure and expertise that could be offered to other developers of conjugate vaccines looking to transition their product candidates from clinical to commercial scale. For Stellar, this is an example of leveraging our KLH core business to expand our potential clinical and commercial opportunities.”

Neovacs CEO, Miguel Sieler, added: “We look forward to working with Stellar Biotechnologies to form this cooperative venture, as they are the leading supplier of KLH protein based on sustainable, scalable aquaculture techniques. Since KLH is a key component of IFNa-Kinoid, this venture is intended to support Neovacs as we work toward potential market launch, as well as bring added value in the field of KLH-Kinoid conjugate vaccines.”

For more information, visit and


Select A Month
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Search


    Select A Category
  • 21st Century Holding Company TCHC (1)
  • 5BARz International Inc. BARZ (12)
  • 5G Wireless Communications Inc. FGWC (8)
  • A.P. Pharma Inc. APPA (3)
  • Abazias Inc. ABZA (2)
  • ABV Gold ABVG (11)
  • ACME Sports & Entertainment Inc. ASEN (2)
  • Adaptive Medias Inc. ADTM (6)
  • Advanced ID Corp. AIDO (5)
  • Advanced Medical Isotope Corp. ADMD (10)
  • Advanced Resources Group Ltd. AVRG (3)
  • Advanced Viral Research Corp. ADVR (9)
  • Advanced Visual Systems Inc. AVSC (10)
  • Advanced Voice Recognition Systems Inc. AVOI (11)
  • Advanced Wound Technologies Inc. AWTM (4)
  • Advaxis Inc. ADXS (2)
  • Agora Holdings Inc. AGHI (4)
  • Ahead of the Bulls (1)
  • AISystems, Inc. ASYI (11)
  • Aladdin Trading & Company ADTD (29)
  • All American Gold Corp AAGC (13)
  • All Asia Licensing Inc. AASI (1)
  • ALL Fuels & Energy Company AFSE (49)
  • All Grade Mining Inc. HYII (3)
  • All Penny Stocks (3)
  • Allarae Healthcare Inc. ALHI (5)
  • Alliance Creative Group ACGX) (15)
  • Alliance Recovery Corp. ARVY (34)
  • APTD (2)
  • Alpine TLI Group Inc. APGR (7)
  • ALR Technologies Inc. ALRT (9)
  • Alternative Construction Technologies Inc. ACCY (10)
  • Alternative Energy Development Corp. ADEC (1)
  • Alternative Fuel Technology Inc. AFTC (1)
  • Alternet Systems Inc. ALYI (29)
  • AM Oil Resources & Technology Inc. AMOR (8)
  • Amarin Corp. AMRN (2)
  • Amaru Inc. AMRU (2)
  • Amerex Group, Inc AEXG (16)
  • American Capital Partners Inc. APRJ (1)
  • American Fiber Green Products Inc. AFBG (1)
  • American Oriental Bioengineering Inc. AOB (3)
  • American Racing Capital Inc. AMRA (2)
  • American Software (2)
  • Amgen Inc. AMGN (2)
  • AmMex Gold Mining Corp. AMXG (2)
  • Ampex Corp AMPX (1)
  • Andover Medical Inc. ADOV (2)
  • Angstrom Microsystems Inc. AGMS (46)
  • Apolo Gold and Energy Inc. APLL (1)
  • Apple Inc. AAPL (13)
  • Aquasil International Inc. AQUS (3)
  • Armco Metals Holdings Inc. AMCO (36)
  • AspenBio Pharma APPY (1)
  • Assured Pharmacy Inc. APHY (1)
  • Asta Funding Inc. ASFI (2)
  • Atlantic Energy Solutions Inc. AESO (1)
  • ATSI Communications Inc. ATSX (1)
  • Augme Technologies Inc. AUGT (70)
  • Auric Mining Corp. AUMY (3)
  • Automated Vending Technologies Inc. AVTC (3)
  • Automotive Company GNAU (11)
  • Avalon Oil and Gas Inc. AOGN (16)
  • Avant Diagnostics Inc. AVDX (25)
  • Avatar Systems Inc. AVSY (3)
  • Axiom Management Inc. AXMA (3)
  • Axis Technologies Inc. AXTG (2)
  • B2Digital Inc. BTOD (18)
  • Balatia Airlines BLTA (2)
  • Bald Eagle Energy Inc. BEEI (18)
  • Banjo & Matilda Inc. BANJ (8)
  • (4)
  • Beacon Enterprise Solutions Group BEAC (47)
  • Beacon Equity Research (552)
  • Beijing Med-Pharm Corp. BGJP (2)
  • Bergamo Acquisition Corp. BGMO (15)
  • Big Tree Group Inc. BIGG (36)
  • Bio-Clean International Inc. BCLE (1)
  • Bio-Matrix Scientific Group Inc. BMSN (1)
  • BioCentric Energy Holdings Inc. BEHL (1)
  • Biomagnetics Diagnostics Corp. BMGP (3)
  • bioMETRX Inc. BMRX (1)
  • Bionic Products Corp. BNPD (4)
  • Biophan Technologies Inc. BIPH (1)
  • BioSolar Inc. BSRC (22)
  • Biotech Holdings Ltd. BIOHF (3)
  • Inc. BZRT (9)
  • Black Diamond Brands Corp. BDMHF (1)
  • Blue Diamond Ventures Inc. BLDV (1)
  • Blue Water Global Group Inc. BLUU (7)
  • Blugrass Energy Inc. BLUG (4)
  • (1)
  • Boreal Water Collection Inc. BRWC (23)
  • Boston Therapeutics Inc. BTHE (20)
  • Bridgetech Holdings International Inc. BGTH (1)
  • Brighton Oil & Gas Inc. BROG (8)
  • Britannia Mining Inc. BMIN (14)
  • Brite Strike Tactical Illumination Products, Inc. BSTI (41)
  • Brookside Technology Holdings Corp BKSD (2)
  • Bullzi Security Inc. BLLZ (3)
  • BWI Holdings Inc. BWIH (165)
  • Cal-Bay International Inc. CBYI (6)
  • Callisto Pharmaceuticals, Inc. (1)
  • Calpian Inc. CLPI (27)
  • CAMAC Energy Inc. CAK (2)
  • Canam Energy Inc. CNGJ (10)
  • CanAm Uranium Corp. CAUI (58)
  • Cannabics Pharmaceuticals Inc. CNBX (14)
  • Capital City Energy Group Inc. CETG (18)
  • Car Monkeys Group CKMY (15)
  • Carbon Sciences Inc. CABN (21)
  • CardioVascular BioTherapeutics Inc. CVBT (5)
  • Cardium Therapeutics Inc. CXM (44)
  • Cascade Technologies Inc. CSDT (2)
  • Cascadia Investment Inc. CDIN (4)
  • Casey Corp. CCPR (1)
  • Cashcow Magazine (4)
  • Cavico Corp. CVIC (3)
  • CD International Enterprises Inc. CDII (23)
  • CDC Corp. CHINA (4)
  • CelebDirect Inc. CELI (3)
  • Cellceutix Corp. CTIX (18)
  • CellCyte Genetics Corp. CCYG (3)
  • Century Group, Inc. CEYG (1)
  • CEOcast (184)
  • CepTor Corp. CEPO (1)
  • Cereplast Inc. CERP (9)
  • Chancery Resources Inc. CCRY (3)
  • Changing Times Vitamins Inc. SGTB (12)
  • CHDT Corp. CHDO (5)
  • Cherubim Interests Inc. CHIT (35)
  • China 3C Group CHCG (13)
  • China America Holdings Inc. CAAH (8)
  • China Direct Inc. CDS (4)
  • China Education Alliance Inc. CEUA (4)
  • China Energy Recovery Inc. CGYV (12)
  • China Growth Development Inc. CGDI (2)
  • China Health Management Corp CNHC (7)
  • China Health Resource Inc. CHRI (14)
  • China INSOnline Corp. CHIO (1)
  • China Jiangsu Golden Horse Steel Ball Inc. CJGH (3)
  • China Logistics Group Inc. CHLO (11)
  • China Media Group Corp. CHMD (2)
  • China Medicine Corporation CHME (5)
  • China Nuvo Solar Energy Inc. CNUV (3)
  • China Organic Agriculture Inc. CNOA (11)
  • China Petroleum and Chemical Corp. SNP (2)
  • China Voice Holding Corp. CHVC (47)
  • China Wind Systems Inc. CWSI (6)
  • China Wireless Communications Inc. CWLC (4)
  • China Yongxin Pharmaceuticals Inc. CYXN (5)
  • China YouTV Corp. CYTV (1)
  • ChinaTel Group Inc. CHTL (1)
  • ChromaDex Corp. CDXC (3)
  • City Capital Corp. CTCC (2)
  • Cityside Tickets CIST (21)
  • CleanTech BioFuels Inc. CLTH (10)
  • Cleantech Transit Inc. CLNO (3)
  • Clearly Canadian Beverage Corp. CCBEF (13)
  • Cleartronic Inc. CLRI (52)
  • Clenergen Corp. CRGE (37)
  • CMG Holdings Inc. CMGO (2)
  • Coastal Integrated Services Inc. COLV (13)
  • Coil Tubing Technology Inc. CTBG (1)
  • Colorado Goldfields Inc. CGFI (5)
  • Colt Resources Inc. COLTF (13)
  • Columbia River Resources Inc. CRVR (1)
  • CoMedia Corp. CMTN (1)
  • CommercePlanet Inc. CPNE (4)
  • Compress Technologies Inc. CTLG (17)
  • Conforce International Inc. CFRI (2)
  • CAJT (9)
  • Cono Italiano Inc. CNOZ (12)
  • Consorteum Holdings, Inc. CSRH (160)
  • ContentChecked Holdings Inc. CNCK (24)
  • Continental Fuels Inc. CFUL (2)
  • Convergence Technology Group Inc. CNVC (7)
  • Copper King Mining Corp. CPRK (2)
  • Cord Blood America Inc. CBAI (102)
  • Crdentia Corp CRDT (12)
  • Creative Vistas Inc. CVAS (2)
  • Crystal International Travel Group Inc. CINT (4)
  • Cubic Energy Inc. QBC (2)
  • Cybermesh International Corp. CYTL (1)
  • Cyclone Power Technologies Inc. CYPW (9)
  • CYIOS Corp. CYIO (1)
  • Daily Views (13)
  • Dakshidin Corp. DKSC (5)
  • Data Call Technologies Inc. DCLT (25)
  • Daulton Capital Corp. DUCP (26)
  • Davi Skin Inc. DAVN (1)
  • Debt Resolve Inc. DRV (2)
  • Debut Broadcasting Corporation Inc. DBTB (1)
  • Deep Blue Marine Inc. DPBM (6)
  • Deep Down Inc. DPDW (15)
  • Deer Valley Corp. DVLY (2)
  • Defense Solutions Inc. DFSH (3)
  • Delta Mining and Exploration Corp. DMXC (1)
  • Dermisonics Inc. DMSI (1)
  • Destination Television Inc. DSTV (17)
  • Dhanoa Minerals Ltd. DHNA (4)
  • DigitalPost Interactive Inc. DGLP (8)
  • Document Capture Technologies Inc. DCMT (3)
  • DoMark International Inc. DOMK (29)
  • Dominovas Energy Corp. DNRG (48)
  • Dragon Capital Group Corp. DRGV (11)
  • Dragon International Group Corp. DRGG (2)
  • Duma Energy Corp. DUMA (20)
  • Duska Therapeutics Inc. DSKA (1)
  • Dutton Associates (88)
  • DXP Enterprises Inc. DXPE (4)
  • Dynamic Media Holdings Inc. DYMH (6)
  • Dynamic Response Group Inc. DRGP (6)
  • Dynasty Limousine Inc. DNYS (19)
  • Earth Dragon Resources Inc. EARH (10)
  • Eastbridge Investment Group Corp. EBIG (1)
  • Ebenefits Direct, Inc. EBFD (21)
  • eCareer Holdings Inc. ECHI (9)
  • Echo Therapeutics Inc. ECTE (5)
  • EcoloCap Solutions Inc. ECOS (2)
  • Ecologic Transportation Inc. EGCT (11)
  • Ecotality, Inc. ECTY (67)
  • eCrypt Technologies Inc. ECRY (79)
  • EdgeTech International Inc. EGIL (6)
  • eDoorways Corp. EDWY (183)
  • Inc. EFSF (4)
  • EFuel EFN Corp. EFUL (1)
  • EGPI Firecreek Inc. EFIR (1)
  • Elephant Talk Communications Corp. ETAK (6)
  • Elephant Talk Communications Inc. ETAK (2)
  • Elleipsis Global Travel Solutions Inc. EGTS (3)
  • Elray Resources Inc. ELRA (11)
  • Elron Electronic Industries Ltd. ELRN (1)
  • Emerging Media Holdings Inc. EMDH (22)
  • Empire Energy Corporation International EEGC (3)
  • Endeavor Explorations Inc. EAVR (7)
  • Endeavour Silver Corp. EXK (3)
  • Endevco Inc. EDVC (2)
  • Energtek Inc. EGTK (61)
  • Enherent Corp. ENHT (2)
  • EnterConnect Inc. ECNI (5)
  • Enterprise Oilfield Group Inc. E.TO (13)
  • EnXnet Inc. EXNT (1)
  • Epazz Inc. EPAZ (22)
  • Equity Stock Analysis (1)
  • ER Urgent Care Holdings Inc. ERUC (6)
  • ERF Wireless Inc. ERFB (15)
  • Essential Innovations Technology Corp. ESIV (2)
  • Inc. ETLC (3)
  • Euoko Group Inc. EUOK (2)
  • EV Innovations Inc. EVII (189)
  • EV Transportation Inc. EVTP (7)
  • Exchange Media Corp. EXMD (9)
  • Exeter Resource Corp. XRA (2)
  • Expert Group Inc. EXPT (5)
  • ExpressIR Inc. (1)
  • Extreme Motorsports of California, Inc. EMOC (26)
  • ezBanc-A Stocklender's Journal (6)
  • Falcon Crest Energy FCEN (75)
  • Falcon Ridge Development Inc. FCNR (2)
  • Famous Uncle Als Hot Dogs & Grille Inc FDOG (10)
  • Fastfunds Financial Corp. FFFC (17)
  • Financial Media Group, Inc. FNGP (26)
  • Financial Services Exchange FSE (1)
  • First Titan Corp. FTTN (45)
  • FlexWeek Inc. FXWK (6)
  • FluoroPharma Medical Inc. FPMI (46)
  • Foldera, Inc. FDRA (11)
  • Force Energy Corp. FORC (5)
  • FormCap Corp. FRMC (29)
  • Fortune Market Media Inc. FTMM (5)
  • Franklin Mining Inc. FMNJ (1)
  • Freedom Leaf Inc. FRLF (12)
  • Fresh Harvest Products Inc. FRHV (7)
  • Fresh Promise Foods Inc. FPFI (12)
  • Freshstart Properties Inc. FSPP (1)
  • FrogAds Inc. FROG (6)
  • Frozen Food Gift Group Inc. FROZ (5)
  •, Inc. FNDM (56)
  • Fushi Copperweld Inc. FSIN (2)
  • Galenfeha Inc. GLFH (28)
  • Gastar Exploration Ltd. GST (2)
  • Gemini Explorations Inc. GXPI (12)
  • Gen2media Corp. GTWO (2)
  • General Environmental Management Inc. GEVI (56)
  • General Metals Inc. GNMT (1)
  • General Steel Holdings Inc. GSI (3)
  • GeoBio Energy Inc. GBOE (1)
  • GeoEye Inc. GEOY (4)
  • GeoPharma Inc GORX (1)
  • Giggles N’ Hugs Inc. GIGL (53)
  • Global Alumina Corp. GLA.U (1)
  • Global General Technologies Inc. GLGT (1)
  • Global Payout Inc. GOHE (38)
  • Global Realty Development Corp. GRLY (10)
  • Global Resource Corporation GBRC (48)
  • Global Roaming Distribution Inc. GRDB (34)
  • GlobalWise Investments Inc. GWIV (129)
  • GNCC Capital Inc. GNCP (24)
  • Golden West Brewing Company Inc. GWBC (3)
  • GoldSpring Inc. GSPG (4)
  • Google, Inc. GOOG (8)
  • (1)
  • Grandview Gold Inc. GVGDF (2)
  • Gray Publishing & Media, Inc. GPMIJ (15)
  • Graystone Park Enterprises Inc. GPKE (7)
  • Great Plains Holdings Inc. GTPH (28)
  • Green Earth Technologies GETG (1)
  • Green Star Alternative Energy Inc. GSAE (2)
  • Green Star Products Inc. GSPI (2)
  • Green Technology Solutions Inc. (GTSO) (19)
  • Greenbelt Resources Corp. GRCO (1)
  • Greenchek Technology Inc. GCHK (18)
  • GreeneStone Healthcare Corp. GRST (2)
  • Greenstone Holdings Inc. GSHN (2)
  • GRILLiT Inc. GRLT (8)
  • Growblox Sciences Inc. GBLX (24)
  • GT Legend Automotive Holdings Inc. GTLA (2)
  • GTX Corp GTXO (40)
  • Gulf Western Petroleum Corp. GWPC (3)
  • GWS Technologies Inc. GWSC (4)
  • Halcyon Jets Holdings Inc. HJHO (15)
  • Hanover Financial Services (17)
  • Harbin Electric Inc. HRBN (2)
  • Harvey Electronics Inc. HRVE (1)
  • Hasco Medical Inc. HASC (7)
  • Hathway Corp. HWYI (1)
  • HeadsUp Entertainment International Inc. HDUP (3)
  • Healthnostics Inc. HNSO (1)
  • HealthSonix Inc. HSXI (1)
  • HealthSport Inc. HSPO (14)
  • Heartland Inc. HTLG (1)
  • Heartland Oil and Gas Corp. HTOG (7)
  • Hemis Corporation HMSO (19)
  • Hemisphere Gold Inc. HPGI (1)
  • Hemp Inc. HEMP (25)
  • Hendrx Corp. HDRX (1)
  • Hi-Shear Technology Corp. HSR (3)
  • HII Technologies Inc. HIIT (8)
  • Holloman Energy Corp. HENC (2)
  • Holmes Osborne (6)
  • Hologic Inc. HOLX (4)
  • Home Shopping Latino Inc. HSPG (8)
  • Hong Kong Highpower Technology Inc. HPJ (2)
  • HotOTC (61)
  • HotStockChat (3)
  • HotStockMarket (HSM) (3)
  • HST Global Inc. HSTC (11)
  • Hunt Gold Corp. HGLC (32)
  • HWI Global Inc. HWIC (3)
  • Hydrogen Corp. HYDG (1)
  • i-Level Media Group Inc. ILVL (3)
  • i2 Telecom International Inc. ITUI (7)
  • iB3 Networks Inc. IBNW (1)
  • IceWEB Inc. IWEB (5)
  • ICP Solar Technologies Inc. ICPR (3)
  • IDGLOBAL Corp. IDGJ (2)
  • IDO Security Inc. IDOI (22)
  • IFAN Financial Inc. IFAN (34)
  • Imaging3 Inc. IMGG (2)
  • ImaRx Therapeutics Inc. IMRX (2)
  • Impact E-Solutions Corp. IESO (1)
  • Imperial Petroleum Inc. IPMN (10)
  • Inca Designs Inc. IDGI.PK (4)
  • Independent Film Development Corp. IFLM (1)
  • Index Oil and Gas Inc. IXOG.OB (5)
  • India Globalization Capital Inc. IGC (4)
  • Industrial Biotechnology Corp. IBOT (1)
  • Infinite Group Inc. IMCI (48)
  • Inform Worldwide Holdings, Inc. IWWI (27)
  • Intec LTD ICLJY (1)
  • IntegraMed America Inc INMD (1)
  • Intelecom Inc. IECM (3)
  • Intelimax Media Inc. IXMD (31)
  • Intelligent Highway Solutions Inc. IHSI (6)
  • Intercept Energy Services Inc. IESCF (7)
  • Interleukin Genetics Inc. ILI (1)
  • International Barrier Technology Inc IBTGF (1)
  • International Consolidated Companies Inc. INCC (2)
  • International Stem Cell Corp. ISCO (193)
  • Inventergy Global Inc. INVT (15)
  • Investor Village (7)
  • Investors Business Daily (4)
  • InvestorsProfs (1)
  • InvestSource (11)
  • IPOs (8)
  • IR Biosciences Holdings Inc IRBS (3)
  • Isonics Corp. ISON (1)
  • ItsAboutFinance (2)
  • JC Data Solutions Inc. JCDS (4)
  • Joytoto USA Inc. JYTO (14)
  • JZZ Technologies Inc. JZZI (3)
  • KAL Energy Inc. KALG (3)
  • Kallo Inc. KALO (43)
  • Kandi Technologies Corp. KNDI (3)
  • KCM Holding Corp. KCMH (3)
  • Kingslake Energy Inc. KGLJ (2)
  • Klondex Mines Ltd. KLNDF (1)
  • Knobias KNBS (5)
  • Kraig Biocraft Laboratories Inc. KBLB (88)
  • L&L International Holdings Inc. LLFH (2)
  • Lantis Laser Inc. LLSR (5)
  • Last Mile Logistics Group LMLG (4)
  • Latitude 360 Inc. LATX (21)
  • LD Holdings Inc. LDHL (14)
  • Legacy Holdings Inc. LGYH (1)
  • Legacy Ventures International Inc. LGYV (24)
  • Legend Media Inc. LEGE (4)
  • Lifespan Inc. LSPN (1)
  • Lime Energy Corp. LIME (3)
  • Lingo Media Corp. LMDCF (17)
  • Linkwell Corporation LWLL (4)
  • Liquor Group Wholesale Inc. LIQR (22)
  • Inc. LFLS (47)
  • LOGIC Devices Inc. LOGC (1)
  • Logility Inc. LGTY (1)
  • LoJack Corp LOJN (3)
  • Longhai Steel Inc. LGHS (10)
  • Lotus Pharmaceuticals Inc. LTUS (1)
  • Low Carbon Technologies (LWCTF) (3)
  • Lucas Energy, Inc. LEI (17)
  • Mabwe Minerals Inc. MBMI (56)
  • Macquarie Infrastructure Company MIC (5)
  • Maine and Maritime Corp. MMA (1)
  • Majic Wheels Corp. MJWL (6)
  • Makeup Inc. MAKU (2)
  • Mammoth Energy Group Inc. MMTE (5)
  • Mantra Venture Group Ltd. MVTG (10)
  • Mariner’s Choice International Inc. MCII (2)
  • Martin Nutraceuticals MNIU (11)
  • Material Technologies Inc. MTCH (44)
  • Max Media Group Inc. MXMI (9)
  • Max Sound Corp. MAXD (30)
  • MC Endeavors Inc. MSMY (2)
  • MedeFile International Inc. MDFI (46)
  • MediaG3 Inc. MDGC (1)
  • Medina International Holdings Inc. MIHI (3)
  • Medisafe 1 Technologies Corp. MFTH (3)
  • Medivisor Inc. MVSR (1)
  • Mega Media Group, Inc. MMDA (30)
  • MegaWest Energy Corporation MGWSF (2)
  • Memry Corp. MRY (2)
  • Metro One Development Inc. MODI (2)
  • Mexico Energy Corp. MXC (1)
  • Micro Identification Technologies Inc. MMTC (44)
  • MicrocapMoney (2)
  • Microsoft Corporation MSFT (4)
  • Midway Gold Corp. MDW (1)
  • Military Resale Group MYRL (19)
  • Minco Silver Corp. MSV.TO (1)
  • Mindpix Corp. MNDP (1)
  • MIP Solutions Inc. MSOL (7)
  • MIT Holding MITD (36)
  • MitoPharm Corp. MTPH (1)
  • Mizati Luxury Alloy Wheels, Inc. MZTI (14)
  • Mobile Entertainment Inc. MBEI (1)
  • Mobile Lads Corp. MOBO (43)
  • Money4Gold Holdings Inc. MFGD (3)
  • Holdings Inc. MBKR (2)
  • Mosquito Consolidated Gold Mines Limited MSQ.V (1)
  • Moxian Inc. MOXC (17)
  • mPhase Technologies Inc. XDSL (12)
  • MSE Enviro-Tech Corp. MEVT (4)
  • Muscle Flex Inc. MFLI (55)
  • MusclePharm Corp. MSLP (23)
  • Mvive Inc. MVIV (22)
  • My Automated Advisor (4)
  • MyECheck Inc. MYEC (99)
  • Inc. MYST (1)
  • Nanogen Inc. NGEN (2)
  • Nanometrics Inc. NANO (1)
  • NanoSensors Inc. NNSR (1)
  • NanoTech Entertainment Inc. NTEK (30)
  • Napster, Inc. NAPS (5)
  • National Automation Services Inc. NASV (67)
  • National Coal Corp. NCOC (2)
  • Naturally Iowa Inc. NLIA (2)
  • NavStar Technologies Inc. NVSR (16)
  • nCoat Inc NCOA (8)
  • Neah Power Systems NPWZ (14)
  • Neohydro Technologies Corp. NHYT (4)
  • Neoprobe Corp. NEOP (6)
  • NeoStem Inc. NBS (6)
  • NetSol Technologies Inc NTWK (64)
  • Neurobiological Technologies Inc. NTII (3)
  • NeuroMama Ltd. NERO (15)
  • Neutra Corp. NTRR (37)
  • New Asia Gold Corp. NWAG (1)
  • New Generation Biofuel Holdings Inc. GNB (3)
  • NewMarket China Inc. NMCH (7)
  • NewMarket Technology Inc. NMKT (7)
  • Newport Digital Technologies Inc. NPDT (61)
  • Nexia Holdings Inc. NXHD (51)
  • NexMed Inc. NEXM (8)
  • NeXplore Corp. NXPC (4)
  • Next One Interactive Inc. NXOI (7)
  • NextGen Bioscience Inc. NXGB (1)
  • NextPhase Wireless Inc. NPHS (1)
  • Nexus Enterprise Solutions Inc. NXES (30)
  • NF Energy Saving Corp. of America NFES (1)
  • Nhale Inc. NHLE (18)
  • Nilam Resources Inc. NILR (4)
  • Nitro Petroleum Inc. NTRO (5)
  • North Bay Resources Inc. NBRI (10)
  • NuTech Inc. NTCI (1)
  • Nutra Pharma Corp. NPHC (13)
  • NutraNomics Inc. NNRX (30)
  • NuVim Inc. NUVM (1)
  • NVIDIA Corp. NVDA (1)
  • NXGen Holdings Inc. NXGH (1)
  • Oakridge Global Energy Solutions Inc. OGES (31)
  • Obee's Franchise Systems Inc. OBFM (1)
  • OBJ Enterprises Inc. OBJE (27)
  • Odyne Corporation ODYC (15)
  • Omega Commercial Finance Corp. OCFN (2)
  • OmniaLuo Inc. OLUO (1)
  • Omnicity Corp. OMCY (26)
  • Omninet Media.Com, Inc. ONMC (5)
  • On The Go Healthcare Inc. MODI (13)
  • On the Move Systems Inc. OMVS (102)
  • Oncolin Therapeutics Inc. OCOL (1)
  • One World Holdings Inc. OWOO (61)
  • Ones to Watch (1,325)
  • Onstream Media Corp. ONSM (5)
  • Onteco Corp. ONTC (4)
  • Open Energy Corp. OEGY (4)
  • Optical Systems Inc. OPSY (2)
  • Oramed Pharmaceuticals Inc. ORMP (2)
  • Organic Alliance Inc. ORGC (2)
  • (82)
  • OtcStockExchange (5)
  • OurPet's Company OPCO (26)
  • OxySure Systems Inc. OXYS (23)
  • P2 Solar Inc. PTOS (24)
  • Pacific Gold Corp. PCFG (3)
  • Pamplona Picks (1)
  • Pan Global Corp. PGLO (82)
  • PanGenex Corp. PGCX (3)
  • Paramount Gold and Silver Corp. PZG (3)
  • Patient Access Solutions Inc. PASO (7)
  • Patriot Energy Corp. dba TelTeck Solutions Inc PGYC.PK (11)
  • Patriot Scientific Corp. PTSC (6)
  • Peace Arch Entertainment Group Inc. PAE (1)
  • Peoples Educational Holdings Inc. PEDH (2)
  • Perf Go Green Holdings Inc. PGOG (12)
  • Perfect Web Technologies, Inc PWBI (11)
  • Perfectenergy International Ltd. PFGY (1)
  • Performance Health Technologies Inc. PFMH (31)
  • Pet DRX Corp. VETS (1)
  • Petro Resources Corp. PRC (2)
  • PetroSun Inc. PSUD (41)
  • Phantom Fiber Corp. PHFB (2)
  • Pilot Financial Communications (3)
  • Pipex Pharmaceuticals Inc. PP (2)
  • PITOOEY! Inc. PTOO (14)
  • Planet Nutrition Inc. PNHL (4)
  • Platina Energy Group Inc. PLTG (8)
  • PlayBOX Inc. PYBX (5)
  • Players Network PNTV (4)
  • Pluristem Therapeutics Inc. PSTI (10)
  • Positron Corp. POSC (3)
  • Power of the Dream Ventures (1)
  • Power Play Development Corp. PWPY (17)
  • Powersafe Technology Corp. PWSF (1)
  • Premier Energy Corp. PNRC (1)
  • Pressure BioSciences Inc. PBIO (41)
  • PRG Group Inc. PRGJ (2)
  • PrimEdge Inc. PEDI (1)
  • Private Equity Securities (93)
  • Pro Motors Group Corp. PMGU (2)
  • Pro Travel Network Inc. PTVL (2)
  • ProGaming Platforms Corp. PPTF (22)
  • Proginet Corp. PRGF (3)
  • Prom Resources PRMO (9)
  • Propalms Inc. PRPM (3)
  • Provectus Pharmaceuticals Inc. PVCT (12)
  • Puget Technologies Inc. PUGE (23)
  • Pulmo BioTech Inc. PLMO (4)
  • Puramed Bioscience Inc. PMBS (3)
  • Pure Biofuels Corp. PBOF (4)
  • Pure H2O Inc. PURH (1)
  • Pure Hospitality Solutions Inc. PNOW (99)
  • Purio Inc. PURO (5)
  • Puritan Financial Group Inc. PTNG (1)
  • Purple Beverage Company Inc. PPBV (8)
  • QED Connect Inc. QEDC (4)
  • Qiao Xing Universal Telephone Inc. XING (2)
  • QPC Lasers Inc. QPCI (3)
  • Qualcomm Inc. QCOM (2)
  • QualityStocks for Women (16)
  • QualityStocks Partner StockGuru (3,878)
  • QualityStocks Stock Newsletter (549)
  • QualityStocks Stock Newsletters (18,158)
  • QualityStocks Video Charts (286)
  • Market Basics (6)
  • Quantum Fuel Systems Technologies Worldwide Inc. QTWW (15)
  • Quantum International Corp. QUAN (3)
  • Quasar Aerospace Industries Inc. QASP (6)
  • QuoteMedia Inc. QMCI (120)
  • Rafarma Pharmaceuticals Inc. RAFA (31)
  • Rainbow Coral Corp. RBCC (33)
  • Rancher Energy Corp. RNCH (9)
  • Raptor Resources Holdings Inc. RRHI (50)
  • Raven Gold Corp. RVNG (3)
  • Red Lake Exploration Inc. RLKX (19)
  • RegalWorks Media Inc. RWMI (4)
  • Regenicin, Inc. RGIN (6)
  • Reliant Financial Services Inc. RFNS (1)
  • Renhuang Pharmaceuticals Inc. RHGP (3)
  • ReoStar Energy Corp. REOS (1)
  • Resort Savers Inc. (RSSV) (10)
  • Revett Minerals (1)
  • Rock Energy Resources Inc. RCKE (4)
  • Rodman & Renshaw (432)
  • Ronn Motor Company Inc. RNNM (6)
  • Rox Resources Ltd. RXRS (3)
  • Royal Quantum Group, Inc. RYQG (10)
  • Royal Standard Minerals Inc. RYSMF (2)
  • Rudy Nutrition RUNU (27)
  • RXi Pharmaceuticals Corp. RXII (3)
  • Santa Fe Gold Corp. SFEG (5)
  • Santa Fe Holding Company SFHD (3)
  • Save The World Air Inc. ZERO (12)
  • Savoy Energy Corp. SNVP (26)
  • SavWatt USA, Inc. SAVW (5)
  • Seabridge Gold Inc. SA (1)
  • Seawright Holdings Inc. SWRI (1)
  • Sector 10 Inc. SECI (78)
  • SES Solar Inc. SESI (2)
  • Seven Arts Pictures plc SAPX (1)
  • Seven Arts Pictures PLC SAPXF (5)
  • Shazam Stocks (22)
  • ShotPak Inc. SHTP (35)
  • Shumate Industries SHMTE (1)
  • Sibling Group Holdings Inc. SIBE (55)
  • Sierra Gold Corp. SGCP (2)
  • Signature Devices Inc. SDVI (9)
  • Silver Dragon Resources Inc. SDRG (1)
  • Silver Falcon Mining Inc. SFMI (1)
  • SilverSun Technologies Inc. SSNT (30)
  • Simtrol Inc. SMRL (74)
  • Simulated Environment Concepts Inc. SMEV (130)
  • Singlepoint Inc. SING (19)
  • Sino Agro Food Inc. SIAF (1)
  • Sinobiomed Inc. SOBM (4)
  • Sinovac Biotech Ltd SVC (1)
  • Sipp Industries Inc. SIPC (2)
  • Skinny Nutritional Corp. SKNY (19)
  • Sky Petroleum Inc. SKPI (1)
  • SkyPostal Networks Inc. SKPN (66)
  • Small Cap Sentinel (2)
  • Small Cap Sleeper (3)
  • Smallcap Bullets (2)
  • (22)
  • SmallCapVoice (426)
  • Smoky Market Foods Inc. SMKY (9)
  • SocialPicks (1)
  • Sofame Technologies Inc SDW.V (1)
  • Sohm Inc. SHMN (14)
  • Solanex Management Inc. SLNX (15)
  • Solar Energy Initiatives Inc. SNRY (14)
  • Solar Wind Energy Tower Inc. SWET (15)
  • Solarfun Power Holdings Co. Ltd. SOLF (2)
  • Soul and Vibe Interactive Inc. SOUL (14)
  • South Sea Energy Corp. SSGY (7)
  • Soyo Group Inc SOYO (2)
  • SpaceDev Inc. SPDV (5)
  • Sparta Commercial Services Inc. SRCO (31)
  • Speedemissions Inc. SPMI (14)
  • Spicy Pickle Inc SPKL (18)
  • SpongeTech Delivery Systems Inc. SPNG (14)
  • Sports Pouch Beverage Company Inc. SPBV (1)
  • Star Mountain Resources Inc. SMRS (10)
  • Start Scientific Inc. STSC (22)
  • Stock Market E-News (1)
  • Stock Promoters (4)
  • StockEgg (14)
  • Stocks to Watch (1,662)
  • StocksJournal (2)
  • StockUPTicks (165)
  • Stockwire (6)
  • Strategic American Oil Corp SGCA (32)
  • Stratos Renewables Corp. SRNW (89)
  • StreamTrack Inc. STTK (31)
  • Striker Oil & Gas Inc. SOIS (4)
  • Sun Motor International Inc. SNMO (1)
  • SUN Sports & Entertainment Inc. SSPE (3)
  • Sunshine Biopharma Inc. SBFM (6)
  • Superlattice Power Inc. SLAT (60)
  • SupportSave Solutions, Inc. SSVE (10)
  • Surefect Holdings Inc. SUFH (1)
  • Suspect Detection Systems Inc. SDSS (37)
  • Sweet Success Enterprises Inc. SWTS (35)
  • Swiss Hawk AG SWHKF (1)
  • Symposium Production Corp. SYPJ (1)
  • Tactical Air Defense Services, Inc. TADF (15)
  • Tao Minerals Ltd. TAOL (1)
  • TapImmune Inc. TPIV (14)
  • Taplmmune Inc. TPIM (1)
  • Technology Applications International Inc. NUUU (25)
  • TechPrecision Corp. TPCS (4)
  • Tecton Corp. TTNC (3)
  • Teknik Digital Arts Inc. TKNK (10)
  • Telanetix Inc. TNXI (2)
  • Teletouch Communications Inc. TLLE (5)
  • Terax Energy Inc. TEXG (32)
  • Terme Bancorp TMEB (1)
  • Terra Nostra Resources Corp. TNRO (25)
  • The Amergence Group AMNG (8)
  • The Aristocrat Group Corp. ASCC (113)
  • The Bowser Report (42)
  • The Bull Report (32)
  • The Capital Report (5)
  • The DIRECTV Group Inc. DTV (1)
  • The Fight Zone Inc. TFZI (12)
  • The Guitammer Company Inc. GTMM (38)
  • The International Traders Expo (30)
  • The Mobile Star Corp. MBST (7)
  • The Motley Fool (3)
  • The Mundus Group Inc. MNDS (1)
  • The Penny Stock Blog (28)
  • The Principal Structure Fund, Inc. PSF (2)
  • The Tracking Corp. TRKG (1)
  • The UpTurn, Inc. UPTR (20)
  • The Wall Street Savant (24)
  • The Wide Angle (3)
  • Thresher Industries Inc. THRR (15)
  • Tidelands Oil and Gas Corp. TIDE (1)
  • Tiens Biotech Group USA Inc. TBV (1)
  • TMT Capital Corp. TMTP (1)
  • TNI BioTech Inc. TNIB (16)
  • Tombstone Exploration Corp. TMBXF (9)
  • TOMI Environmental Solutions Inc. TOMZ (4)
  • Tootie Pie Company, Inc. TOOT (11)
  • Torchlight Energy Resources, Inc. TRCH (2)
  • TradeShow Marketing Company Inc. TSHO (21)
  • TransWorldNews (4)
  • Tri-Star Holdings Inc. TSHL (31)
  • Trimax Corp. TMXN (31)
  • TripleCrownStocks (9)
  • True 2 Beauty Inc. TRTB (43)
  • TwinTrader (8)
  • TXP Corporation TXPO (1)
  • TZ Ltd. TZL.AX (1)
  • U.S. Mine Makers Inc. USMM (1)
  • uKarma Corporation UKMA (1)
  • Ultitek Ltd. UITK (21)
  • Unbridled Energy Corporation TSX-UNE (21)
  • Unico Inc. UNCO (3)
  • Universal Bioenergy Inc. UBRG (3)
  • Universal Detection Technology UNDT (41)
  • Universal Energy Corp. UVSE (19)
  • Universal Property Development and Acquisition UPDA (4)
  • Universal Tracking Solutions Inc. UTRK (13)
  • Universal Travel Group UTVG (14)
  • UpSNAP Inc. UPSN (1)
  • Uranium Energy Corp. UEC (64)
  • Uranium Hunter Corp. URHN (17)
  • Urex Energy Corp. URXE (1)
  • USA Recycling Industries Inc. USRI (21)
  • USA Superior Energy Inc. USSU (9)
  • Ustelematics Inc. UTLM (27)
  • Utah Uranium Corp. UTUC (2)
  • Utilicraft Aerospace Industries Inc. UITA (2)
  • ValueRich & iValueRich (9)
  • Vaporin Inc. VAPOD (2)
  • VentriPoint Diagnostics Ltd. VPTDF (26)
  • Vermillion Inc. VRML (3)
  • Vertical Branding Inc. VBDG (11)
  • VIASPACE, Inc. VSPC (185)
  • Victory Energy Corp. VYEY (29)
  • Vidshadow Inc. VSHD (1)
  • View Systems Inc. VSYM (16)
  • Viper Networks Inc. VPER (2)
  • Viral Genetics Inc. VRAL (3)
  • Viropro International Inc. VPRO (2)
  • VirTra Systems Inc. VTSI (22)
  • Viscount Systems Inc. VSYS (27)
  • visionGATEWAY Inc. VGWA (1)
  • VistaGen Therapeutics Inc. VSTA (104)
  • Visualant Inc. VSUL (5)
  • Vital Products Inc. VTLP (5)
  • Viyya Technologies Inc. VYON (2)
  • VizStar Inc VIZS (24)
  • Voiceserve Inc. VSRV (18)
  • Vortex Resources Corp. VTEX (7)
  • Vsurance Inc. VSUR (3)
  • Vyteris Inc. VYHN (1)
  • W2 Energy Inc. WWEN (13)
  • Wall Street News Alert (76)
  • WallStreetGrapevine (12)
  • WaterPure International Inc. WPUR (4)
  • Wave Systems Corp. WAVX (5)
  • Week in Review (2)
  • Well Power Inc. WPWR (77)
  • Wescorp Energy Inc. WSCE (18)
  • West Canyon Energy Corp. WCYO (1)
  • Western Standard Energy Corp. WSEG (7)
  • Who's Your Daddy Inc. WYDI (7)
  • WikiLoan Inc. WKLI (14)
  • Wind Energy America Inc. WNEA (3)
  • Wisdom Homes of America Inc. WOFA (15)
  • Wits Basin Precious Minerals Inc. WITM (2)
  • Woize International Ltd. WOIZ (1)
  • WordLogic Corp. WLGC (40)
  • Workstream Inc. WSTM (9)
  • WorldWater & Solar Technologies Corp. WWAT (10)
  • Worldwide Energy and Manufacturing WEMU (12)
  • Worldwide Manufacturing USA Inc. WWMU (6)
  • WRIT Media Group Inc. WRIT (32)
  • X-Change Corp. (XCHC) (2)
  • Xaar Plc XAARF (1)
  • Xenomics Inc. XNOM (1)
  • XsunX Inc. XSNX (17)
  • XZERES Corp. XPWR (2)
  • Younger America YNGR (13)
  • Zacks Investment Research (11)
  • ZAGG Inc. ZAGG (9)
  • Zaldiva Inc. ZLDV (3)
  • ZAP ZAAP (15)
  • ZBB Energy Corp ZBB (7)
  • Zenosense Inc. ZENO (53)
  • Zentric Inc. ZNTR (14)
  • Zevotek Inc. ZVTK (8)
  • Znomics Inc. ZNOM (3)
  • Newsletter Signup

    Stay ahead of the pack with QualityStocks and receive "The QualityStocks Daily", our summary formatted newsletter containing stock tips from hundreds of online investment newsletters.

    Rotate your device 90° to view site.
    apcalissx online drugs
    situated comer suffer
    schon volunteers stunden zullen
    unfortunately calculate calculator poulos
    infection educational ruptures levofloxacin information never practices lawyers johnson
    represent legal stories populous commission claimant counted employer serves
    author products reference largest support check maintain fracture koolhydraten because aging roaming
    worst class skull childrens first program ioana posted england clustering
    decide saturday tickets discover natural funding serving universities
    company satisfaction writer format these however seekers provided
    begins travel essays great testament electronic martin might custom assignment
    blood genital contact suction videos months sucks about
    whoever someone shaughnessy levels staat professionals features states after
    florida caught science colleges felon bulldogs american north tried
    index micro materials holidays miniature customercentric starter nation assistance